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It has recently been shown that the binding site of SAHase, an enzyme critical 
in the replication mechanism of viruses, is quite flexible and exhibits a large 
difference between the "open" and "closed" conformations, thus presenting an 
obstacle towards design efforts. As a possible solution to this dilemma, we have 
strategically designed and synthesized a series of structurally innovative nucleosides 
possessing a heteroaromatic purine ring split into its two components (for example, 
an imidazole and pyrimidine ring), thereby conferring additional degrees of 
conformational freedom and torsional flexibility to the ligand. As a result, these 
molecular "chameleons" can adapt to the environment of the flexible binding site in 
order to maximize and complement structural interactions, without losing the 
integrity of the crucial contacts involved in the enzyme's mechanism of action. The 





BACKGROUND AND SIGNIFICANCE 
 
According to Alfred Burger,1 medicinal chemistry “remains a challenging 
science, which provides satisfaction to its practitioners.  It intrigues those of us who 
like to solve problems posed by nature.  It verges increasingly on biochemistry and on 
all the physical, genetic and chemical riddles in animal physiology which bear on 
medicine.  Medicinal chemists have a chance to participate in the fundamentals of 
prevention, therapy and understanding of diseases and thereby to contribute to a 
healthier and happier life.”  Medicinal chemistry is defined as an interdisciplinary 
science situated at the interface of organic chemistry and the life sciences such as 
biochemistry, pharmacology, molecular biology, immunology, pharmacokinetics and 
toxicology on one side and chemistry-based disciplines such as physical chemistry, 
crystallography, spectroscopy and computational modeling on the other.2 
 Medicinal chemistry has been practiced for several thousand years as was 
indicative from Pen-t’sao, a book of herbs by the Chinese Emperor Shen Nung. 2  
The root Dichroa febrifuga, known as Ch’ang Shan during the emperor’s reign, was 
prescribed for the treatment of fevers.2  Ironically, this root contains alkaloids, a 
natural product containing a basic nitrogen, which is now found in pharmaceutical 
drugs for malaria.  Ma Huang, now known as Ephedra sinica, was used as a 
heartstimulant, diaphoretic agent and cough suppressant.  Ma Huang contains 
ephedrine which is used to treat bronchial asthma and raise blood pressure.  
 2 
In this “prescientific” period, the majority of remedies were discovered by 
chewing on cinchona bark, roots, leaves and berries, as evidenced by the written 
records of the Chinese, Indian, South American, Middle Eastern and Mediterranean 
cultures.2  Only within the last 150 years have scientists searched for the active 
components of these medicinal agents.2 Although little of modern-drug therapy is 
based on these “prescientific” remedies, it is fascinating to observe that the approach 
to the practice of medicinal chemistry has developed from such a fundamental 
process. 
 Development of drug therapy progressed rapidly after the discovery of DNA 
as the primary genetic material in 1944 and subsequent elucidation of the physical 
structure in 1953.3  Since the nucleic acids DNA and RNA are the initial precursors in 
the formation of proteins that are responsible for many biological and physiological 
processes, it is logical that these molecules could be viewed as potential targets for 
drug design and development.4  DNA and RNA are biopolymers composed of 
nucleosides held together by phosphodiester linkages, as a result, the nucleosides can 
also be considered as potential targets.3,4 
 In 1909, the term “nucleoside” was proposed by Levene and Jacobs to 
describe carbohydrate derivatives of purines and pyrimidines.5  The nucleoside 
constituents of RNA and DNA are composed of a sugar moiety, -D-ribofuranose and 
2’-deoxyribose--D-ribofuranose respectively, linked to either a purine (adenine or 
guanine) or pyrimidine (cytosine, thymine or uracil) heterocyclic base via a 
glycosidic bond, through the N-9 of the purine or the N-1 of the pyrimidine base 
(Figure 1).  The purine bases adenine and guanine, as well as the pyrimidine base 
 3 
cytosine, are common to both DNA and RNA whereas the pyrimidine base thymine 




Figure 1.  The naturally-occurring nucleosides in DNA and RNA. 
 
 It was not until the 1960’s, that chemistry involving nucleosides and 
nucleotides provided the fundamental infrastructure and synthetic methodology 
necessary to produce numerous biologically active naturally occurring and 
structurally modified nucleosides.  The biological activity of anticancer agents such 
as 5-fluoro-2’-deoxyuridine (FUDR), arabinosylcytidine (ara-C), 8-azainosine, along 
with the discovery of a potent antiviral nucleoside, arabinosyladenosine (ara-A), and 
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antitumor agent, toyocamycin revealed the potential value of modified nucleoside 
analogues as chemotherapeutic agents (Figure 2).6,7   
 
 
Figure 2.  Some FDA-approved nucleoside drugs. 
 
 
The importance of these nucleoside analogues was later confirmed with the 
emergence of HIV as the main etiological agent of AIDS.8  The first drug approved 
for the treatment of HIV was the modified nucleoside AZT which inhibits HIV-1 
reverse transcriptase.9  Furthermore, several other nucleoside analogues involved in 
inhibition of HIV-1 reverse transcriptase, namely ddC, ddI, d4T and 3TC, have 
provided even more significance to the use of nucleoside analogues as biologically 
potent chemotherapeutic agents (Figure 3 on the next page).8,10,11 
Despite these examples, clinical use of these drugs is limited due to several 
factors, including toxicity, the wide range of side effects, problems with lipophilicity 
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and crossing cell membranes, and susceptibility to enzymatic cleavage.11  This has 
prompted researchers to search for more advanced chemotherapeutic agents that 
could address these issues.  Some of the approaches pursued for “second generation” 
nucleosides included structural modifications to either the sugar moiety or to the 




Figure 3.  Some potent nucleoside-based inhibitors of HIV-1 RT. 
 
One structural modification that has proven valuable is the replacement of 
nitrogen atom or atoms, within the heterocyclic ring scaffold, with a methine group to 
form for example, 1-deaza, 3-deaza, 7-deaza or 9-deazapurine nucleoside analogues 
(Figure 4).   The deazapurine modified nucleosides have been extensively studied and 




Figure 4.  Heteroaromatic purine ring and ribosyl numbering. 
 
Montgomery et al first synthesized 3-deazaadenosine,12 which exhibited 
potent biological activity and surprisingly, did not undergo phosphorylation at the 5' 
position.  Moreover, 3-deazaadenosine has been shown to inhibit S-
adenosylhomocysteine hydrolase,13 a widely recognized enzymatic target for 
antiviral, antiparasitic and anticancer agents.  Some of the 7-deazanucleosides such as 
tubericidin, toyocomycin and sangivamycin have exhibited significant antitumor 
activity in vivo (Figure 5 on the next page).11,14  The 7-deazanucleosides have 
potential advantages over conventional purine nucleosides, as in the case of 
tubercidin.  These advantages include stability towards both adenosine deaminase 
(ADA) and purine nucleoside phosphorylase (PNP), enzymes which are involved in 
biologically important pathways.15,16  Hence, these modified purine-based nucleosides 





Figure 5.  Examples of biologically significant 7-deazapurine nucleosides. 
 
 Modification of N-1 to a methine group within the heteroaromatic purine 
affords the 1-deazapurines which disrupts the hydrogen-bonding within Watson-Crick 
base pair and ultimately disturbs protein synthesis.  1-Deazaadenosine and its 
analogues have shown to possess potent antitumor activity17 as well as to be an 
inhibitor of ADA18 and blood platelet aggregation.19 
 Another purine modification that has been extensively studied is the 
replacement of the methine groups, especially at C-2 and C-8, with a nitrogen atom 
resulting in 2-azaadenosine and 8-azaadenosine respectively (Figure 6).  8-
Azaadenosine, as well as 8- azainosine and 8-azaguanosine, have exhibited potent 
anticancer activity in vivo (Figure 7 on the next page).20   
 
 




Figure 7.  Biologically potent 8-azapurines. 
 
Furthermore, when these 8-azanucleosides are phosphorylated by kinases into 
their respective monophosphate forms, they are incorporated into RNA thereby 
disrupting protein synthesis.7  2-Azaadenosine, a fluorescent nucleoside, has 
displayed modest in vivo activity against both murine L1210 leukemia cells and rat 
mammary tumor cell lines.21 
 Combining both deaza and aza components in a heterocyclic purine moiety 
has resulted in other biologically potent purine modified nucleosides.  For instance, 8-
aza-7-deazaadenosine resulted in moderate activity against PNP.  Additionally, 8-aza-
1-deaza-6-chloropurine nucleosides are known to inhibit PNP as well as to exhibit 
moderate antiviral activity against the polio (Sb-1) virus (Figure 8). 22 
 
 
Figure 8.  Biologically potent modified nucleosides. 
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Further approaches to the modifications of purines have involved the 
incorporation of other heteroatoms such as sulfur or oxygen, which allows the 
heterocyclic moiety to retain its aromaticity.  Modifications involving other 
heteroaromatic bases such as pyrimidines have not been as extensively studied as 
purines, however, their modifications have primarily resulted in aza/deaza 
pyrimidine-based nucleosides and extended pyrimidine ring systems.  5-Azacytidine, 
along with its 2’-deoxy analogue, has displayed significant biological activity against 
L1210 leukemia cells and is presently used clinically in the treatment of acute 
leukemia.23  3-Deazauridine, another modified pyrimidine-based nucleoside, has also 
shown significant biologically activity against leuekemia24 and as well as inhibitory 
activity against CTP synthetase,25 an enzyme involved in cytosine nucleotide 
metabolism (Figure 9).  
 
 
Figure 9.  Biologically potent modified pyrimidine-based nucleosides. 
 
Another structural modification that has been extensively used is the isosteric 
replacement of the furanose oxygen of the sugar moiety with a methylene subunit  
(where X = CH2) resulting in a carbocyclic nucleoside (Figure 10 on the next page).   
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Figure 10.  Some modifications of the ribose moiety. 
 
This modification transforms the glycosidic bond from an unstable hemiaminal to a 
more stable tertiary amine which endows the nucleoside with the ability to resist 
cleavage by phosphorylases, as well as to increase its overall lipophilicity.26  The 
naturally occurring carbocyclic nucleosides aristeromycin and neplanocin A and their 
4’,5’-unsubstituted analogues have shown significant biological activity against both 
SAHase and DNA MeTase, another important enzymatic target for antiviral, 
antiparasitic and anticancer agents (Figure 11).27,28  Although the carbocylic 
nucleosides are synthetically challenging, a generation of extremely potent antiviral 
carbocyclic nucleosides such as carbovir, abacavir and lobucavir have been produced 




Figure 11.  Naturally occurring carbocyclic analogues (Ari and NpcA) and their 




Figure 12.  Extremely potent antiviral carbocylic nucleosides. 
 
Approaches to Drug Development and Design 
In order to design a “perfect” drug it is essential to identify the cause for the 
disease since most diseases result from one of these major causes; one, an imbalance 
of certain chemicals in the body, two, from the invasion of a virus or a foreign 
organism, or three, from abnormal cell growth.2  This imbalance can often times be 
overcome by inhibition of a particular enzyme, interference with DNA replication or 
inhibition of certain biosynthetic pathways within the virus.   
Once the pertinent biochemical system is identified, a prototypical or lead 
compound, is sought which has exhibited desirable biological and pharmacological 
effects but may have some unfavorable properties such as toxicity, insolubility, or 
metabolism problems.2  There are several traditional approaches to the identification 
of a lead compound; these include random screening or nonrandom screening of 
various types of compounds, drug metabolism studies or even clinical observations of 
the affects of a drug.2  Once a lead compound is identified, systematic structural 
modifications are undertaken which include homologation, chain branching, ring 
chain transformations and bioisosterism resulting in a structure-activity relationship 
study.   
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For instance, a homologous series of compounds, where each successive 
compound differs by a simple structural unit, generally a –CH2 group, is synthesized 
to hopefully produce an increased pharmacological response.4  Another variation that 
can be made is the “transformation” of straight chains into branched chains which 
will inherently affect the lipophilic relationship and ultimately alter the potency of a 
compound.  Another common modification of a side chain is the conversion of alkyl 
substituents into their corresponding cyclic analogues.4  The potential for this 
approach was clearly observed in the development of the highly potent HIV-RT 
inhibitor Abacavir, in which the C-6 amino group was alkylated with a cyclopropyl as 
opposed to an n-propyl group, thereby increasing the potency significantly (Figure 12 
on the previous page).  Finally, bioisosterism is a technique that is widely used to 
modify lead compounds into safer and more clinically effective chemotherapeutic 
agents by exchanging an atom or group of atoms with a similar atom or group of 
atoms.4  Bioisoteres are classified as either classical or nonclassical bioisosteres.  
Classical bioisosteres are those groups which have similar steric and electronic 
features but may or may not have a different number of atoms as compared to the 
structural moiety for which they are used as a replacement.4  In contrast, nonclassical 
bioisosteres do not obey the strict steric and electronic definition of classical 
isosteres, and they do not have the same number of atoms as the moiety for which 
they are used as a replacement.4  These isosteres are capable of maintaining similar 
biological activity by imitating the spatial arrangement, electronic properties, or some 
other physiochemical property of the structural piece or functional group that is 
critical for the retention of biological activity.  Regardless of the type of modification, 
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it is expected that successful structural modifications to a lead compound will lead to 
greater biological activity as well as to eliminate any undesirable characteristics. 
Since the interaction of a drug with an enzyme is extremely specific, usually 
only a small fragment of the lead compound, known as the pharmacophore, may be 
involved in the necessary interactions which lead to biological activity.2  Further 
systematic structural manipulation of the pharmacophore results in second generation 
analogues of lead compounds, usually provides useful information regarding 
structure-activity relationships.2  This information can then be exploited to construct 
an even better drug with an improved therapeutic index which is a measure of the 
ratio of the undesirable to desirable drug effects. 
As straightforward as it may seem to develop new inhibitors for known 
enzymes, there are many factors to consider when designing potential inhibitors for a 
particular enzyme binding site.  These include variable energies for an enzyme’s 
conformations, multiple binding modes and even differential solvation effects.2,4  
More importantly, it is necessary to consider the conformational changes of not only 
the inhibitor, but the enzyme to predict optimal binding, which, even if achieved does 
not guarantee activity. 
The first attempt to explain the specificity of enzyme interactions was 
formulated by Emil Fischer in 1894.3  Fischer termed his hypothesis as a “lock and 
key” mechanism (Figure 13 on the next page),29,30 and stated “the specificity of an 
enzyme (the lock) for its substrate (the key) arises from their geometrically 
complementary shapes.”  This theory was ultimately shown to be flawed since it 
suggested that enzymes only have one optimal substrate and other substrates, as 
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similar as they might seem, do not “fit” as well and therefore catalyze reactions less 
efficiently.  Therefore, the drawback is that if the active site has a rigid structure, it 







Figure 13.  (a)  The enzyme’s active site and the substrate.  (b)  The lock and key 
model.  
 
Obviously, this is not true for all cases since some enzymes can catalyze 
reactions for a range of different substrates.  In order to explain this observation, 
Daniel Koshland proposed that the enzyme does not have to be in the appropriate 
conformation required for the substrate to bind, rather the enzyme is forced into a 
conformational change in order to adopt the optimal shape to accommodate the 
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binding of substrates to the active site.  This mode of action, termed as “induced fit”, 
explains why enzymes can accommodate a range of substrates (Figure 14).31-33  A 
related model to the “induced fit” theory is “conformational selection” theory which 
hypothesizes that a particular conformation of the binding site exists that has the 
appropriate geometry for biological activity, but that conformation is only a small 
percentage of the various conformations that the enzyme is capable of, therefore not 
highly populated.34-36  Overall, the induced fit and conformational selection models 
are significantly different from the “lock and key” model since they both display the 
importance of protein flexibility.  Flexibility may play an active role in binding 
specificity due to the interactions produced upon binding structurally distinct 
molecules to structurally distinct protein conformations.   
 
 




 Historically, prior to the availability of sophisticated instrumentation, 
structural information such as highly resolved X-ray crystal structures or high field 
solution NMR structures of enzymes and enzyme-ligand binding complexes, 
scientists were forced to elucidate the parameters of active sites by several methods.2,4  
One such approach involved the synthesis and biological testing of large numbers of 
potential inhibitors that closely resembled the basic structure of the natural substrate 
of an enzyme.  Once the natural substrate or lead compound was identified, 
systematic alterations of the functional groups on the molecule were done in order to 
develop more potent chemotherapeutic agents.2   
Another approach involved the systematic modification of the dimensional 
parameters of a ligand to analyze the enzyme’s active site.  Leonard et al introduced 
this innovative approach37-40 to the nucleoside community by expanding the purine 
ring system, whereby a spacer ring (or rings) was inserted in some fashion between 
the two rings of the purine heterocycle, or, extended out from a pyrimidine 
nucleoside.  This led to a variety of shape-modified heterocycles, most notably his 
lin-, dist-, and prox-benzo-separated heterobases and nucleosides (Figure 15).37-42    
 
 
Figure 15.  Leonard’s benzo-separated adenine analogues. 
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His pioneering work with extended and expanded purine and pyrimidine 
nucleosides and nucleotides provided an excellent foundation for using shape-
modified nucleosides as dimensional bioprobes to help elucidate structural 
information about enzymes, as well as to study recognition and binding properties. 
Enzymes such as purine nucleoside phophorylase, phosphoryl transfer 
enzymes such as adenosine kinase, adenylate kinase and pyruvate kinase, hydrolyzing 
enzymes such as ATPase, as well as other enzymes such as adenosine deaminase and 
xanthine oxidase, were explored, since purines are recognized in these enzymatic 
systems. 37-41  Unfortunately, these analogues ultimately proved limited in their 
utility, partially due to their inherent rigidity.42 
Although this approach to drug design was rational, it remained random, 
tedious and of course, expensive.  The explosion of cutting-edge computer 
technology and methodologies to calculate molecular properties have made it 
increasingly possible to use computer techniques to aid the drug discovery process.  If 
the three-dimensional structure of the target enzyme is available from X-ray 
crystallography, preferentially co-crystallized with a ligand so that the interactions of 
the binding site with the ligand are known, it is reasonable to investigate the enzyme-
ligand complex by computational molecular modeling.  In this way, a detailed 
knowledge of the interactions between the ligand and the enzyme may be obtained.   
Potential candidate ligands can then be docked into the binding site in order to predict 
if the new structure can interact with the enzyme in an optimal way. 
Today, crystal structures for many enzymes are readily available, and this has 
facilitated a more sophisticated approach to the design of new drugs.  Computer-
 18 
assisted structure-based drug design has emerged as a new tool in medicinal 
chemistry.  The drug design cycle approach shown in Figure 16 begins with creating 
a computer model of an enzyme-binding site based on known crystallographic data.  
Next, potential inhibitors or ligands are then docked into the binding site; the 
computer model of the enzyme- substrate complex is subjected to energy 
minimization using innovative computer modeling programs.  Based on the 
computational analysis of structural interactions between the enzyme and several 
different potential substrates; the most promising inhibitors are then synthesized.   
 
 
Figure 16.  Computer-assisted structure-based drug design. 
 
Each of the targets is then assayed to determine the levels of affinity (Ki) for 
the enzyme and the activity against the enzyme (IC50).  Additionally, potential 
inhibitors may also be “soaked” into a preformed crystal of the enzyme to determine 
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enzyme-substrate interactions via X-ray crystallography.  All the collected data is 
then evaluated, fed back into the algorithm, and used to design a second generation of 
inhibitors.   
 Despite the significant advances made in recent years, this approach is still in 
its formative years and not without numerous failures.  For example, it is not 
uncommon that the “best guess” inhibitor analogues predicted by sophisticated 
computer modeling programs ultimately prove to be biologically inactive.  One early 
example of this was the work carried out by Ealick et al with purine nucleoside 
phosphorylase (PNP),43,44 an enzyme involved in the purine salvage pathway of cells.  
PNP exists as a homotrimer of approximately 100 kDa subunits with three identical 
active sites (Figure 17).45   
 
 
Figure 17.  Purine Nucleoside Phosphorylase.
45 
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The nucleophilicity of the phosphate ion of PNP assists in cleaving the 
nucleoside into a free purine base and a phosphorylated sugar.  The free purine 
moiety can then be destroyed or recycled by the cell (Figure 18).45  The design of 
PNP inhibitors is extremely vital to the stability of antiviral and anticancer agents as 
well as to the suppression of T-cell activity.  Since many nucleoside-based anticancer 
and antiviral agents are similar to their natural purine nucleoside, they are recognized 
by PNP, thereby undergoing cleavage into their cellular components and hence 
diminishing their therapeutic value.  Furthermore, recent compelling evidence has led 
researchers to believe that PNP is required for the proper functioning of T-cells, 
however, it does not affect other cellular components of the immune system.  Many 
autoimmune disorders such as psoriasis, rheumatoid arthritis, multiple sclerosis, 
systemic lupus erythematosus, and insulin-dependent diabetes have abnormally 




Figure 18.  Mechanism of Purine Nucleoside Phosphorylase. 
 
 Using molecular modeling programs, Montgomery and coworkers46 designed 
several ligands that appeared to have the greatest binding affinity for the crystalline 
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structure of PNP which is essentially identical to human forms of the enzyme.  
Unfortunately, the “ideal” ligand, identified by molecular modeling proved to be 
biologically inactive for PNP.46  Further studies finally revealed that the binding site 
of PNP was not static, but rather, underwent significant conformational changes upon 
binding different ligands.46  PNP possessed a “swinging gate” of residues that would 
open to allow a wide variety of ligands to bind, at which point the “gate” would then 
close, thereby giving the appearance of a perfect fit, when in reality, it was not.46 
 While most programs on the market today have the ability to consider ligand 
flexibility, few programs are capable of accurately predicting the consequences of 
flexibility when modeling enzyme binding sites.47-49  This is a direct consequence of 
the limitations of the structural information utilized by the program; the origin of this 
structural information is the X-ray crystallographic coordinates of the crystallized 
enzyme, which in reality is merely a static “snapshot” of the enzyme-ligand complex.  
Furthermore, until quite recently, it was believed that only one ideal conformation of 
the complex was responsible for the biological activity, however, the ever-increasing 
availability of crystallographic structures has now revealed that many enzymes are 
capable of adapting a variety of conformations.50-55  This may offer forth more than 
just increased inhibitory activity; this also presents unique prospects towards the 
optimization of other desirable properties for potential drugs such as metabolic 
stability, bioavailability, and formulation.  Given these findings, it is clear that new 
and more innovative approaches for identifying chemotherapeutically viable enzyme-
ligand conformations are vital to the design of new and more potent inhibitors. 
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 Prior to the development of sophisticated docking programs that take into 
account flexibility of both the enzyme as well as the ligand and the absence of highly 
resolved X-ray crystal structures of various enzymes, scientists were forced to use 
very fundamental  approaches to study enzyme-ligand interactions.   
 Approximately 60 years elapsed since the first computation of the steric 
energy calculation in terms of nonbonded interactions.  Westheimer and Mayer56 
calculated the steric contribution as a means to rationalize the rates of racemization of 
optically active diphenyl compounds.  They used mathematical functional forms, and 
the idea of calculating molecular energy from them was suggested by Hill.57  
Approximately 40 years ago, the first use of an electronic computer to calculate and 
optimize the molecular energy was made by Hendrickson.58  He evaluated simple 
energy functions for angle bending, torsional twisting, and nonbonded contributions 
to perform functional analysis and find minimum energy geometries for cycloalkanes 
most notably, cyclopentane, cyclohexane, and cyclohexane.58 
 The impetus for much of the thinking about drug design in the late 1970s and 
early 1980s was the perception that random screening – so successful in the early 
days of antibiotics – was no longer likely to be an efficient strategy for drug 
discovery due to the process being extremely tedious and expensive.58  Two 
technological advances of this period have had major impact on the discovery of new 
therapeutic agents: routine determination of macromolecular structures and the 
application of molecular biology to produce large quantities of high-purity proteins 
for assays and structural use.  The interest in structure-based or structure-assisted 
design came from the early ideas of Ehrlich and Fischer, who proposed a geometric – 
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lock and key analogy – for drug action.29,30  This powerful idea has been the model of 
receptor fitting, pharmacophore matching, and database searching, despite general 
acknowledgement that it has many shortcomings, including failure to account for the 
multiple conformational states possible in ligands and enzymes.   
 In the past few years, investigators using three-dimensional search methods 
have begun to explore the conformational flexibility of potential ligands.59  Whereas 
storing multiple conformations of a single molecule is conceptually simple, it is 
limited by the amount of storage space and by the linear increase in search time with 
the number of molecules to be searched.  It is impossible to ensure that the 
conformation being sought will be among those stored, even with systematic search 
algorithms, because of the chance that the conformation of the bound ligand is not a 
minimum-energy structure in the absence of the enzyme.59  Instead of storing 
multiple conformations, some approaches encode the distances accessible to pairs of 
atom centers.  These accessible distances are used during the search to select 
molecules that could match a particular query, and the matching conformations are 
generated for only those compounds.  Other approaches adjust torsional angles to 
match the query.  Unfortunately, flexible searching has been shown to significantly 
increase the amount of computer time required for searching.59   
 Initial attempts to accommodate enzyme flexibility in drug design were 
through a technique deemed “soft docking”, which was introduced by Jiang and 
Kim.60  The flexible enzyme is immobilized and a “soft”-scoring function is used to 
determine enzyme-ligand affinity.  Scoring functions are used for two purposes; one, 
they optimize the placement of the ligand and, two, rank each ligand in the database 
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for which a docking solution has been found.48,61  On the other hand, soft-scoring 
functions provide some insight into the flexibility of the enzyme by allowing a small 
amount of overlap between the ligand and enzyme.62  However, this technique only 
accommodates for small conformational changes of the enzyme;48,62 hence the search 
for a more effective algorithm continued. 
 During the mid 1990s, several plausible solutions, using multiple protein 
structures, to overcome ligand flexibility and docking were introduced.63-66  One such 
solution was a “grid” approach was developed that precalculate grids on interaction 
energy based on the enzymatic target.63  By extrapolation of the adjacent grid points, 
the interaction energy for a specific conformation is then calculated.63,67 Programs 
such as Autodock or DOCK then perform simulated annealing in the space of the 
flexible ligand.63,67  Although grid-based method has shown to calculate binding 
energies efficiently, it is still remained ambiguous as far as introducing enzyme 
flexibility to the system.67 
Another approach involves an incremental construction algorithm, which is 
based on genetic algorithms (GAs) and a tree-search technique, was created to hinder 
the flexibility of the ligand as well as the enzymatic binding site thereby significantly 
reducing the time required for these calculations.67,68 GAs are based on Darwinian 
selection and utilize the operators selection, crossover, and mutation.  The algorithm 
is based on a known compound (i.e. a chromosome) and proceeds in generations 
where some molecules are selected and modified using the crossover or mutation 
operators.67,68   Crossover involves swapping fragments between molecules that 
occupy the same volume of space.  Mutations include translation, rotation, rotation 
 25 
about a bond, changing a bond type, adding or removing a fragment, and changing an 
atom type.67,68  In each generation, there is a greater likelihood that the fittest 
members will be selected for modifications.  For example, the chromosomes used in 
the GA of Jones et al encode the orientation of the ligand via hydrogen bonding 
interactions with the enzyme.  However, randomly changing the torsional degrees of 
freedom of side chain residues could lead to overlapping structures with extremely 
poor energy.68 
Due to the high demands in procedures for docking flexible ligands in a 
flexible enzymatic binding site, Apostolakis et al69 developed a novel approach that 
relies on Monte Carlo minimization (MCM) and combination of minimization with 
shifted nonbonded interactions (MSNI).  The algorithm is designed such that Monte 
Carlo minimization runs are executed on the low energy enzyme-ligand conformers.69  
Their model had some significant advantages which include allowing unrestricted 
flexibility in the enzymatic binding site and a more rigorous determination of the 
solvation free energy in the evaluation of structures.69   
Recently, Calson et al48,70-72  presented a new “dynamic” pharmacophore 
model based on multiple protein structures that incorporate the inherent flexibility of 
the enzymatic active site and reduces the propagation of errors in an individual 
protein conformation.  The flexibility of the active site is determined by collecting an 
ensemble of conformational models from molecular dynamics (MD) simulation, 
several crystal structures or multiple NMR structures which can be referred to as 
multiple “snapshots” of the active site.48,70-72  Each of these “snapshots” are subjected 
to a series of multi-unit search for interacting conformers (MUSIC) simulations, a 
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Monte-Carlo simulation that calculates multiple, gas-phase minimizations for 
numerous ligands within the enzyme’s active site.48,70-72  The abundant conformations 
of the enzyme were overlaid to reveal the specific regions of the binding site that 
interact with the functional groups of the ligands to ultimately define a 
pharmacophore model for potential inhibitors.48,70-72   
Although these new approaches and programs are promising,72 they still have 
major limitations, especially regarding the programs inability to incorporate the 
flexibility of both the ligand and enzyme.  Therefore, it was our hypothesis that 
pairing a flexible ligand into a flexible binding site would provide an ideal match to 
aid in investigating the structural requirements of various enzyme binding sites.  By 
permitting both the flexible enzyme and flexible ligand to adjust to each other, the 
best possible fit would most likely be achieved and maintained, since both the 
enzyme and the inhibitor would naturally want to achieve their lowest energy state.  
The lowest energy for the enzyme-inhibitor complex may then also be the most 
highly populated state, which was most likely to be the conformation that would 
crystallize.  By crystallizing the most highly populated conformation of the enzyme-
inhibitor complex, it should provide vital information with regards to the interactions 
between the ligand and the active site of the enzyme, and thereby aid in the design of 
more powerful inhibitors. 
That said, one problem logically could be anticipated would be the 
unfavorable entropic cost that would result from binding.  In an enzymatic reaction 
where the enzyme is inherently flexible, it will most likely distort to bind the ligand.  
The favorable binding energy between the “perfect” ligand and the flexible enzyme is 
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used to compensate for the conversion to the entropically unfavorable, yet active 
enzyme-ligand conformation.  If the enzyme is more rigid, the initial binding of the 
ligand will most likely be energetically unfavorable because (i) the enzyme is 
disordered and (ii) it is beneficial for the active site of the enzyme to be 
complementary to the structure of the transition.  Despite the possible energetic loss 
in entropy, we believed the potential for new or more stable hydrogen bonding 
interactions between a flexible ligand and the structurally flexible binding site would 
compensate for any entropic cost. 
 
S-Adenosyl-L-homocysteine hydrolase  
Recently, the threat of biological terrorism has drawn attention to our inherent 
vulnerability to a variety of diseases, both old and new.  Pathogens most likely to be 
used in such weapons must possess certain characteristics; facile transmission, 
longevity outside of the human body, and most importantly, a high mortality rate.  
One such example is smallpox, a particularly virulent member of the orthopox 
viruses.  Smallpox has plagued mankind for centuries, but in 1977, the last confirmed 
case of smallpox was diagnosed and in 1980, the World Health Organization (WHO) 
announced that the orthopox virus genus had been eradicated after an aggressive 50-
year international campaign of vaccination.  Since then very few cases have been 
reported and vaccinations have ceased, making the general population vulnerable to 
variola due to its high mortality rate, which is greater than 60%.  While 
immunizations were recently reinstated, albeit in a very limited capacity, there is still 
no agent available that can be used to treat already infected individuals and the 
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current vaccine cannot be used in immunocompromised individuals.  As a result, 
millions could be infected within a short period of time since, as the recent outbreak 
of Sudden Acute Respiratory Syndrome (SARS) has shown, mankind is more mobile 
than ever and as a result, an outbreak can spread rapidly from one side of the globe to 
the other. 
 Some newer emerging pathogens include the filoviruses Ebola and Marburg 
viruses present serious challenges to medicinal chemists.73  These viruses cause 
severe hemorrhagic fevers, and mortality has been in nearly 90% of the reported 
cases.  Ebola virus was first identified in Africa in 1976, but little is known about the 
histories of these viruses.  There are no specific treatments available, and Ribavarin, a 
nucleoside antiviral agent that has seen success in many diseases, has no effect on 
either Marburg or Ebola.73,74  As a result, the development of an effective 
chemotherapeutic target is crucial. 
 One approach to the design of chemotherapeutic agents active against viral 
pathogens is to target steps central to viral replication.  An ideal enzymatic target is 
one in which there is (i) no equivalent in the normal cell, (ii) the cellular analogue is 
not inhibited within the range of concentrations that would inhibit the viral enzymatic 
target, or (iii) the virally encoded enzyme differs significantly in structure from the 
normal analogue.  An additional issue that must be considered is the development of 
resistant viral stains, which can quickly render a previously potent inhibitor useless.  
The commonly used reverse transcriptase inhibitors, AZT and 3TC are perfect 
examples of this problem; recent studies have shown that drug resistant viral strains 
are becoming increasingly problematic for patients treated with these drugs even after 
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a few days of treatment.50,51,53,75  More recent investigations with tenofovir, an acyclic 
nucleoside RT inhibitor, as well as another RT inhibitor, etravirine, have both 
remained active against a variety of mutant viral strains. Arnold et al have shown that 
if an inhibitor has the ability to be flexible, it endows the inhibitor with a greater 
capacity to adapt to viral mutations, thereby retaining potency against viral resistance 
mechanisms.  Therefore, an additional requirement for design chemotherapeutic 
agents must be to consider options to overcome drug resistance mechanisms.50,51,53,75   
 In that regard, S-adenosyl-L-homocysteine hydrolase (SAHase) is an 
important cellular target for antiviral drug development.13,27,73,76,77  Inhibitors of 
SAHase can indirectly inhibit DNA methyltransferase by a biofeedback 
mechanism.78-80  The byproduct of all S-adenosylmethionine (SAM)-promoted 
methyltransferase reactions is S-adenosylhomocysteine (SAH) (Figure 19), therefore 
SAH is a potent competitive inhibitor of all methylation reactions dependent upon 
SAM as the methyl donor, including DNA MeTase.78-80  SAM is the most ubiquitous 
methyl donor thus SAM dependent methylations are considered to be the most 
important biologically.  Moreover, SAHase is the only known enzyme able to remove 
SAH in mammals.   
 
 
Figure 19.  Conversion of S-Adenosylmethionine to S-Adenosylhomocysteine. 
 30 
As depicted in Figure 20, following the methyl transfer, SAM is readily 
converted into SAH, which is subsequently hydrolyzed by SAHase into its two 
cellular components, adenosine (Ado) and homocysteine (Hcy), requiring assistance 
from an enzyme-bound cofactor, NADH.80  Inhibition of SAHase by nucleoside 
analogues involves depletion of the NADH cofactor, which causes an intracellular 
accumulation of SAH, thereby significantly elevating the SAH/SAM ratio.80  This 
imbalance in the SAH/SAM ratio results in cessation of SAM-dependent 
methylations which leads to hyper- and hypo-methylated DNA.80  As a result, 




Figure 20.  Inhibition of SAHase and its effect on methyltransferases. 
 
More evidence of the biological significance of methylations is that a 
eukaryotic messenger RNA (mRNA) must possess a methylated 5’-cap for stability 
against phosphorylases and ribonucleases.83,84  This “capped” structure is also 
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required for proper binding to ribosomes, and for the promotion of splicing. 83,84 
Therefore, an improperly “capped” mRNA is much less likely to be translated into its 
respective protein, and replication is disrupted.  In particular, the 5’-terminal 
guanosine nucleotide, as well as the penultimate nucleotide residue are subsequently 
methylated by mRNA nucleoside N-7-guanine- and 2’-O-methyltransferases; if these 
transferases are inhibited, incomplete methylation of the cap structure occurs and 
replication is inhibited (Figure 21). 81-84 
 
 
Figure 21.  Methylated 5’ cap of mRNA. 
 
Palmer and Abeles have determined the mechanism of catalysis of SAH 
(depicted in Scheme 1 on the next page).85  The hydrolysis of SAH is an equilibrium 
reaction favors the formation of SAH with a Keq of 10
-6 M.85  The overall reaction 
proceeds in the hydrolysis direction due to the cellular removal of adenosine by its 
conversion into ATP and inosine, as well as the conversion of homocysteine into 
methionine and cystathionine.  The mechanism begins with the oxidation of 
3’hydroxyl group of SAHase by an enzyme bound NAD+.  Lysine, a basic amino acid 
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bound within the enzyme, deprotonates at the C-4 position from the 3’-keto-Ado form 
to afford a carbanion that subsequently eliminates the C-5’ homocysteine group in 
order to form an exocyclic -bond.  The resulting 3’-keto-4’,5’-dehydro-Ado 
undergoes a Michael-type addition of H2O to produce the 5’-hydroxy group.  Next, 
the 3’-keto functionality is reduced by enzyme bound NADH to afford adenosine and 






Mammalian SAHase is a homotetramer of approximately 48,000 kDa 
molecules (432 amino acid residues per subunit), each of which is complexed with a 
cofactor, NAD+.86-88  Four virtually spherical subunits are arranged to afford a flat, 
square tetramer with an opening in the center allowing for a potential substrate to 
dock (Figure 22 on the next page).  The SAHase monomer is structurally similar to 
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NAD+-dependent dehydrogenases with the substrate, SAH, and cofactor, NAD+, 
binding sites located in a cleft between two domains.  The significant difference 
between SAHase and NAD+-dependent dehydrogenases is representative in the NAD+ 
binding site of SAHase since NAD+ requires significant interactions from two protein 
monomers, specifically amino acid residues Tyr430 and Lys426.88 
 
 
Figure 22.  S-Adenosylhomocysteine hydrolase.
88 
 
 SAHase undergoes a significant conformational change between the NAD+ 
and NADH forms of the enzyme within each catalytic cycle.89  NADH and its 
oxidized form, NAD+, show considerable differences in their hydrodynamic 
 34 
properties which suggests that SAHase will most likely adopt a far more compact 
conformation on NAD+ reduction and substrate oxidation.90,91  From the crystal 
structure resolved by Turner et al,88 the inhibitor, 3’-keto-DHCeA, is immersed 
deeply within the active site located in a cleft between two domains of each subunit in 
the NADH form.  However, in the recently solved crystal structure of rat SAHase, the 
NAD+ form shows an open catalytic site in the absence of an inhibitor.92  It has been 
shown that there exists a hinged motion associated within domain I of each subunit of 
SAHase during the enzymatic reaction, since domain II of each subunit is mainly 
involved with the adjacent subunits, thus creating a conformational change between 
the “open” and “closed” forms of SAHase (Figure 23 on the next page).93 
 Based on Turner’s crystal structure of SAHase88 complexed with the inhibitor, 
it has been noticed that domain I and II are interconnected by two bent linkers; linker 
I, amino acid residues 184-186 and linker II, amino acid residues 350-360).  Since 
amino acid residues Lys186, Asp190, His353, and Met358 within linkers I and II are 
involved in binding to the oxidized C4’ position inhibitor in the enzymatic site, it is 
plausible that this binding induces “bending” of the two linkers, hence the mobile 
domain I moves towards the stationary domain II thereby sealing the active site to 
enclose the substrate.  In the “closed” conformation, two histidine residues; His55 





















In the past 20 years there have been many SAHase inhibitors identified, many 
of which structurally resemble adenosine since it is the natural substrate of SAHase. 
These have since been separated into three categories; first, second and third 
generation inhibitors, based on their record of discovery.  First and second generation 
inhibitors are also termed type I mechanism-based inhibitors, which inhibit the 
enzyme by serving as substrates for the 3'-oxidative activity of SAHase and 
converting it from the active form (NAD+) to the inactive form (NADH).  
Alternatively, third generation inhibitors are defined as type II mechanism-based 
inhibitors which are activated by the SAHase and irreversibly inactivate the enzyme 
through covalent modification.  Throughout the many years of searching for a 
“magic” inhibitor of SAHase, these subsequent generations of inhibitors have become 
increasingly more potent as well as to exhibit significantly greater enzyme specificity. 
 During the 1970’s and 80’s SAHase was deemed as an attractive target for the 
design of potentially effective antiviral inhibitors.95  These inhibitors were either 
irreversible; such as neplanocin A (NpcA) and aristeromycin (Ari) which are 
naturally occurring carbocyclic analogues, or competitive such; as 3-deazaadenosine, 
3- deazaneplanocin A, and 3-deazaaristeromycin (Figure 24).96,97  
 
 
Figure 24.  Some potent carbocyclic nucleosides that inhibit SAHase. 
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NpcA was a particularly interesting SAHase inhibitor since it has a unique 
mechanism of action.  Upon binding NpcA to the active site of SAHase, NpcA is 
oxidized by enzyme-bound cofactor NAD+ to form the 3’-keto-NpcA and 
subsequently NAD+ is converted into its reduced form NADH.  This induces a 
conformational change into the “closed” conformation of SAHase, therefore trapping 
the 3’-keto-NpcA resulting in cessation of enzymatic action.  This phenomenon is 
known as a “cofactor depletion” mechanism, and any compound that inhibits SAHase 
via this particular mechanism is referred to as type I mechanism-based inhibitor. 
 NpcA, a first generation inhibitor, was indeed one of the most biologically 
active agents.27,98,99  Since NpcA could be easily phosphorylated into its triphosphate 
form using a series of enzymes; adenosine kinase, adenylate kinase, and nucleoside 
diphosphate kinase, it closely resembled ATP which resulted in NpcA being 
extremely cytotoxic.27,98,99  Based on the cellular toxicity of NpcA and several other 
first generation inhibitors of SAHase, the search continued for less toxic analogues. 
In an effort to overcome the cellular toxicity of the first generation inhibitors, 
two different methodologies were applied in order to design more effective SAHase 
inhibitors.  The first approach involved the modification of the cyclopentyl moiety, 
more specifically removal of the 4’-hydroxymethyl substituent of Ari and NpcA to 
provide the subsequent 4’,5’-tetrahydro and 4’,5’-unsaturated derivatives (Figure 25 
on the next page).100  Both of these analogues were shown to irreversibly inhibit 
SAHase via the type I mechanism.101  More significantly, they were not substrates for 




Figure 25.  4',5'-tetrahydro and 4',5'-unsaturated derivatives of Ari and NpcA. 
 
The second approach involved the modification of the heterocyclic base, more 
specifically removal of the N-3 of adenine in both Ari and NpcA resulting in 3-
deazaaristeromycin (3-deazaAri) and 3-deazaneplanocin A (3-deazaNpcA) 
respectively.  This modification was made due to the potent inhibition of SAHase by 
3-deazaadenosine which produced a simultaneous formation of S-3-
deazaadenosylhomocysteine in addition to an increase in SAHase (Figure 26).13  
Hence, based on the effective inhibition of 3-deazaadenosine, the next logical step 
was to synthesize the 3-deaza carbocyclic analogues.   
 
 




It was thus shown, inhibition of SAHase by 3-deazaAri was reported to be 
significantly greater than that of Ari.27,102  Similarly, inhibition of SAHase by 3-
deazaNpcA was determined to be reversible and competitive.27,102  Furthermore, the 
cytotoxicity of the 3-deazaAri and 3-deazaNpcA was significantly reduced due to the 
as yet unexplained ability for 3-deaza nucleoside analogues to avoid phosphorylation 
by adenosine kinase.27,102 
More recently, several research groups attempted to design a series of type II 
mechanism based SAHase inhibitors.  These inhibitors are catalytically activated by 
SAHase and subsequently become covalently bound the enzyme.  In 1991, Jarvi et al 
synthesized (Z)-4’,5’-didehydro-5’-deoxy-5’-fluoroadenosine which showed to 
possess inhibitory activity against SAHase.103  Initially, the mechanism was thought 
to function via a type II mechanism pathway, where the enzyme was inhibited by 
reduction of NAD+ to NADH and the subsequent elimination of the fluoride ion 
(Scheme 2 on the next page, pathways b and b’).   However, it was later shown that 
the mechanism involved the rapid addition of water at the 5’ position, and subsequent 
elimination of the fluoride ion followed by NAD+ cofactor depletion (Scheme 2 on 
the next page, pathway a).104  Surprisingly, the enzyme’s hydrolytic activity 
functioned independently from its oxidative activity which implied that (Z)-4’,5’-
didehydro-5’-deoxy-5’-fluoroadenosine was actually a “pro inhibitor” for a type I 
mechanism based inhibitor for SAHase.  Based on this unique mechanism of 
inactivation of SAHase by (Z)-4’,5’-didehydro-5’-deoxy-5’-fluoroadenosine, many 
attempts have been made to exploit the enzyme’s hydrolytic activity to convert a “pro 
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inhibitor” into either a type I mechanism based “inhibitor”, or, an electrophilic 






 One such substrate for SAHase was (E)-5’,6’-didehydro-6’-deoxy-6’-
halohomoadenosines.105  The mechanism of action was determined to be the addition 
of water across the 5’,6’- bond of the nucleoside analogue affiliated with the 
reduction of enzyme-bound NAD+ to NADH.105   Conversion of the possible “pro 
inhibitor” to its subsequent “inhibitor” form was proportional to the stability of the 
eliminating halogen.  Although (E)-5’,6’-didehydro-6’-deoxy-6’-halohomoadenosines 
were biologically inactive for SAHase,105 it appeared that by taking advantage of their 
“5’,6’-hydrolytic activity”, potent inhibitors could possibly be designed. 
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 In 1998, Borchardt et al synthesized and characterized the first type II 
mechanism-based inhibitor that relied solely on the enzyme’s hydrolytic activity.105  
It was shown that the maximum inhibition of the enzyme was 83% and much to their 
delight, the original content of NAD+ and NADH remained unchanged.105  Based on 
3H-labeling studies, the mechanism of action by which 6’-bromo-5’,6’-didehydro-6’-
fluorohomoadenosine (Figure 27) inhibits SAHase, revealed that immediately 
following the “hydrolytic activity” and elimination of bromine, Arg196 
nucleophilically attacked the electrophilic substrate resulting in the formation of an 
amide bond and concurrent loss of fluorine ion.105 
 
 
Figure 27.  Some type II mechanism based inhibitors. 
 
The knowledge that the binding site of SAHase was quite flexible and 
exhibited a large difference between the “open” and “closed” conformations,90 
combined with the recent findings that flexible inhibitors can over come drug 
resistance mutations in viral HIV,50,51,53,75 led us to believe that inhibitors possessing 
variable degrees of flexibility could be a potential solution to overcome the flexibility 
of SAHase.  Many nucleoside based inhibitors,27,100,102,105-108 most of them 
structurally rigid, have been employed as enzyme inhibitors in antiviral drug design, 
however, we have strategically designed a novel series of split nucleosides referred to 
 42 
 
Figure 28.  General structure of distal and proximal fleximers. 
 
as “fleximers” (Figure 28).   This new class of unique shape-modified nucleosides 
introduces flexibility to the heteroaromatic purine ring by “splitting” it into its two 
components (for example,  an imidazole and pyrimidine ring), thereby conferring 
additional degrees of conformational freedom and torsional flexibility to the ligand 
while still retaining the molecular elements necessary for recognition.  As a result, 
these molecular “chameleons” can adapt to the environment of the flexible binding 
site in order to maximize and complement structural interactions, without losing the 
integrity of the crucial contacts involved in an enzyme’s mechanism of action.  It is 
our hypothesis that endowing these structurally unique nucleosides with torsional 
flexibility will result in (i) increased inhibitory properties against biologically 
significant enzymes such as SAHase, (ii) increased ability to overcome viral 
resistance mechanisms, and (iii) will provide valuable insight toward increasing our 
understanding of enzyme/ligand structure and function, and as such they will serve as 
the foundation for the design of a new generation of chemotherapeutic agents. 
 While nucleosides have long been employed as enzyme inhibitors in 
chemotherapeutic drug design, there are surprisingly few examples of analogues 
structurally similar to the fleximers.  The most striking example, initially reported by 
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Herdewijn et al in 1995, has exhibited potent biological activity against herpes 
simplex virus (HSV).109,110  These analogues also possess a “split” scaffold, albeit 
“reversed” in their connectivity, with a pyrimidine ring connected to the sugar 
moiety, rather than the five membered ring system found in purines (Figure 29).   
 
 
Figure 29.  Herdewijn’s “reversed” fleximers. 
 
The C-5 position of the six-membered uracil ring is substituted by a series of 
five-membered heterocyclic ring systems that include thiophene, furan and 
cyclopentadiene rings.  The results of a detailed structure activity study revealed that 
the key to their biological activity was their ability to adjust their conformational 
geometry in order to sample better hydrogen bonding interactions between the 3’ and 
5’ hydroxyl groups of the 2’-deoxyribofuranose moiety in the binding site of HSV-
thymidine kinase (TK). 109,110  Furthermore, the 5-substituted heterocyclic ring 
systems with small or no substituents showed that favorable hydrophobic interactions 
were occurring with the active site of HSV-TK. 109,110  After a series of rationally 
designed molecular modifications, it was shown that replacement of ring carbons with 
electronegative atoms resulted in improved interactions with the positive electrostatic 
potential within the enzyme’s active site by compromising the favorable hydrophobic 
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interactions. 109,110  Hence, structural modifications of the 5-substituted heterocyclic 
ring systems to improve the hydrophobicity while maintaining the interaction energy 
has become a considerable challenge. 
Soon after these “reversed fleximers” were introduced, a group in Sweden 
published111 the synthesis of several related analogues, although little biological data 
were reported.  The potent biological activity of Herdewijn’s flexible analogues, 
while admittedly against a different enzymatic target, is highly promising and clearly 
lends support to our fleximers, however, given their reversed connectivity and their 
close structural similarity to thymidine as well as their inhibition of thymidine kinase, 
these analogues should be considered as examples of C-5 substituted pyrimidine 
nucleosides, rather than purine analogues. 
To our knowledge, the only other example in the literature of a split 
nucleoside was recently introduced by Weisz et al,112,113 whose connectivity more 
closely resembles our fleximers since the imidazole ring is connected to the sugar 
moiety, and the C-4 of the imidazole ring is substituted with either a pyridine or 
benzene ring (Figure 30).   
 
 
Figure 30.  Weisz’s imidazole-pyridine or imidazole-benzene fleximers. 
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In contrast to our fleximers, the connectivity of the six-membered ring is 
attached at the C-3 of the benzene ring (or the C-2 of the pyridine ring), rather than 
the C-5 or C-6 of the pyrimidine ring, thereby detracting from the standard purine 
motif.  As a result, we believe our analogues are more true to a classic purine design.  
Weisz has not yet reported any biological investigations for his analogues, but rather, 
has employed his analogues to investigate triple helix formation in DNA, an 
interesting application for our analogues that could be pursued in the future. 
 Initially, Seley et al designed and synthesized a series of distal-
fleximers,114,115 more specifically the adenosine, guanosine and inosine analogues in 
efforts to resolve the aforementioned problems (Figure 31).  Analogous to Leonard’s 
dist-benzo analogues,39 these fleximers are connected via a carbon-carbon single 
bond from the C-5 of the imidazole moiety to the C-6 of the pyrimidine ring.  After 
performing a series of ab initio quantum mechanical structure optimization 
calculations on the fleximers, it was observed that these shape-modified nucleosides 




Figure 31.  Previously synthesized distal-fleximers. 
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Furthermore, each of the fleximer analogues was modeled within SAHase to 
determine the degrees of conformational freedom and torsional flexibility.  Using 
automated molecular docking (InsightII, Discover/Accelrys), Monte Carlo simulation, 
followed by simulated annealing revealed that the dist-fleximers, with exception of 
the guanosine fleximer, occupied a region in the SAHase active site in an orientation 
similar, but not identical to, the position of the known nucleoside inhibitor in the 
crystal structure published by Turner et al.  The guanosine fleximer proved to be 
quite interesting; the lowest energy conformation revealed that the heterocyclic 
moieties had adopted a syn-like conformation, bending back over the sugar to form a 
curved structure.116  More significantly, the pyrimidine moiety exhibited a degree of 
twist, essentially reversing the substituents to allow the fleximer to take advantage of 
intramolecular hydrogen bonding between the carbonyl of the pyrimidine and the 5’-
hydroxyl of the sugar moiety.116 
Following their synthesis, the fleximers and their corresponding parent 
nucleosides were assayed against SAHase.  The adenosine fleximer was an alternative 
substrate for the enzyme, albeit worse than adenosine itself, while the inosine was a 
poor substrate, exhibiting weak enzymatic activity.116  To our surprise, the guanosine 
fleximer inhibited the enzyme in the hydrolytic direction nearly twice as effectively 
as it did in the synthetic direction.  This observation was unprecedented, since no 
other guanosine nucleoside has ever been reported to inhibit SAHase.116  Our 
modeling efforts showed that the guanosine fleximer is twisting dramatically to place 
the C-2 amino group where the adenosine’s amino group would normally reside.  
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Interestingly, this twist essentially mimics the inverted structural arrangement of 
isoguanosine (isoG) (Figure 32). 
 
 
Figure 32.  Twisted prox-guanosine 3 and prox-isoguanosine 4 fleximers. 
 
Based on the design and synthesis of the distal fleximers,114,115 we have turned 
our attention to a second series of flexible nucleosides collectively known as proximal 
fleximers (Figure 33).  Since these second generation fleximers represented a new 
class of potential SAHase and antiviral inhibitors as yet uncharacterized, we felt it 
prudent to focus our initial synthetic efforts with rational stages.   
 
 





Figure 34.  Synthetic targets proximal adenosine and inosine. 
 
First, proximal adenosine and inosine were targeted (Figure 34 on the top of 
the page), in order to establish a basis (adenosine) for comparison with later 
analogues.  Proximal inosine was a synthetic target that could be realized easily from 
adenosine.  Next, based on surprising inhibitory information from the distal 
guanosine fleximer,116 we sought out to synthesize the proximal guanosine along with 
its structural isomer, proximal isoguanosine such that we can “prearrange” the 
substituents in the conformation they appeared to prefer thereby resulting in a more 
favorable binding energy, since theoretically the pyrimidine moiety would not have to 
expend any energy to attain the desired conformation (Figure 32 on the top of 
previous page).    Finally, two more synthetic targets arose out of the synthetic 
pathway of the prox-guanosine and –isoguanosine, which were the synthetic 
intermediates, proximal diamino and xanthine analogues (Figure 35 on the next 



















We initially modeled a carbocylic fleximer, 4’,5’-unsaturated-3-deazaNpcA 
fleximer, due to its close similarity with Borchardt’s potent SAHase inhibitor, 4’,5’-




Figure 36.  Borchardt’s SAHase inhibitor and its analogous fleximer. 
  
and the Affinity and Discover modules from Accelrys.  PDB file 1A7A for SAHase 
was used, which had been crystallized with Borchardt’s analogous 4’,5’-unsaturated-
3-deazaNpcA nucleoside in the binding domain.88  Borchardt’s substrate was 
removed and a fleximer inserted, and the new complex minimized.  Using Infighter’s 
Monte Carlo simulation, followed by simulated annealing, the binding conformation 
with the lowest intermolecular binding energy was predicted.  This method utilized 
the constant valence force field (cvff) and allowed the ligand and binding site side 
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chains to be flexible.  The fleximer was allowed to minimize using a conjugate 
gradient method.  The difference in the planar biaryl ring system of the “rigid” 
nucleoside to the nearly 90 degree perpendicular twist of the “relaxed” biaryl ring 
system of the fleximer showed the ability of the fleximer showed the ability of the 
fleximers to draw on their inherent structural flexibility to attain the optimal 
conformation.  Upon comparison, the 3-deazaNpcA fleximer exhibited several new 
hydrogen bonding interactions not observed with Borchardt’s analogue as well as -
stacking between the imidazole and the imidazole ring of His353 (Figure 37).   
 
 
Figure 37.  4’,5’-unsaturated-3-deazaNpcA fleximer and Borchardt’s analogue. 
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Both analogues exhibited interactions between His55 and Thr157, but the 
fleximer exhibited additional interactions between Asn346, His353, and Glu156, 
while Borchardt’s analogue showed interaction with only Lys186 and Thr57.  The 
calculated binding energies differed by nearly 10 kcal/mol, with the more favorable 
energy (-26.83 kcal/mol) calculated for the enzyme/fleximer complex (Table 1).  
While this was highly encouraging, we realized that we needed to establish a more 
solid foundation for comparison, and hence we focused on the adenosine, inosine and 
guanosine fleximers.   
 
Table 1.  Ab initio modeling results. 
COMPOUND BINDING ENERGY (KCAL/MOL) 
4’,5’-enyl-3-deazaNpcA –16.38 
4’,5’-enyl-3-deazaNpcA Fleximer –26.83 
 
 Next, to gauge the level of conformational flexibility in the context of an 
enzyme active site, all three distal fleximers were modeled in SAHase.  Using 
automated molecular docking (InsightII, Discover from Accelrys), Monte Carlo 
simulation, followed by simulated annealing revealed that the distal fleximers, with 
the exception of the guanosine fleximer, occupied a region in the SAHase active site 
in an orientation that is similar to, but not identical to, the position of the known 
nucleoside inhibitor in the crystal structure published by Turner et al (Figure 38 and 
39 on pages 53 and 54 respecitively).  The crystallographic water molecules in the 
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original structure for the active site were retained as they also interacted with the 
fleximers. 
 The distal guanosine fleximer, as shown in Figures 40 and 41 (on pages 54 
and 55), proved to be quite interesting; the lowest energy conformation revealed that 
the heterocyclic moieties had adopted a syn-like conformation, bending back over the 
sugar to form a curved structure.  More significantly, the pyrimidine moiety exhibited 
a high degree of twist, essentially reversing the substituents to allow the fleximer to 
take advantage of intramolecular hydrogen bonding between the carbonyl of the 

















Figure 41.  Distal guanosine exhibiting intramolecular hydrogen bonding. 
 
Following their synthesis,114,115 the distal fleximers and their corresponding 
parent nucleosides were assayed against SAHase.  As shown in Table 2 on the next 
page, the adenosine fleximer was an alternative substrate for the enzyme, albeit worse 
than adenosine itself, while the inosine a worse substrate, but exhibiting weak 
enzymatic activity.  To our surprise, the guanosine fleximer showed activity on both 
the synthetic and hydrolytic activity directions with Ki values of 217 and 128 M, 
respectively.  While these values are not spectacular since aristeromycin and 
neplanocin A have Ki values in the nanomolar range against SAHase, they are notable 
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since, to our knowledge, no guanosine nucleosides have ever been reported to exhibit 
activity against SAHase. 
 




Km (µM) Kcat (m
-1
) Ki (µM) 
Synthesis Direction    
Adenosine 0.82 ± 0.004 91.2 ± 0.2 nd 
Adenosine Fleximer 54.4 ± 1.1 0.56 ± 0.04 nd 
Inosine 2.5 ± 0.03 44.2 ± 0.7 925 ± 21 
Inosine Fleximer  421 ± 5.7 0.005 ± 0.003 422 ± 16 
Guanosine 844 ± 6.6 0.06 ± 0.02 1472 ± 32 
Guanosine Fleximer ns ns 217 ± 13 
Hydrolysis Direction:    
SAHase and G-
fleximer 
6.6 ± 0.2 28.3 ± 1.2 128 ± 18 
 
nd – not determined; ns – not a substrate  
 
Based on the work on the distal fleximers, our initial calculations had shown 
that the binding energy for the distal guanosine fleximer was –24.88 kcal/mol, but 
these had been carried out on a lower level of theory, using a class one force field 
(CVFF), so in an effort to increase our accuracy, we moved to a Class II force field 
(CFF) and repeated the calculations.117,118  Since the form of an energy surface is 
usually very complex, especially for large molecules or systems, with many energy 
minima and barriers and regions of greatly varying energy and curvature, the cff force 
field expands the analytical energy expression to include terms needed for an accurate 
model of the energy surface.61  The new results all showed lower binding energies 
than for the previous force field with the new energy for the distal guanosine being 
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used as the reference in this study.  The corresponding proximal guanosine fleximer 
was 5.36 kcal/mol lower in energy than the distal analogue, however, as we 
predicted, both the distal and proximal isoguanosine fleximers exhibited much more 
favorable binding energies. Relative to the distal guanosine fleximer, the distal and 
proximal isoguanosine fleximers were more favorable by –20.59 and –21.97 kcal/mol 
respectively. The structures shown in Figure 42 have been artificially overlaid, 
aligning each by their sugar moieties. From this one can see that the bases for each of 




Figure 42.  Proximal guanosine and isoguanosine fleximers aligned at C-3 and C-




The isoguanosine fleximers, distal and proximal, have two tautomeric forms, 
and our calculations showed that the distal substituted isoguanosine fleximer 
preferred to exist as the N3(H) tautomer (shown in Figure 43), with a binding energy 
of –53.79 kcal/mol, rather than the N1(H) (–35.70 kcal/mol), while the proximal 
isoguanosine fleximer, preferred the N1(H) tautomeric form (shown in Figure 44 on 
the next page) with a binding energy of –55.17 kcal/mol, in contrast to the N3(H) 









Figure 44.  N1(H) tautomer for the proximal isoguanosine fleximer in SAHase. 
 
Figure 45 (on the top of the next page) depicts the proximal and distal 
guanosine, as well as the isoguanosine aligned in the binding site of SAHase by the 
residues they interact with. As mentioned above, the proximal and distal isoguanosine 
fleximers exhibit the most favorable binding energy values (Table 3 on the next 
page), but it is clear that they are both capable of adopting a significantly different 
conformation from each other, while still maintaining critical contacts necessary for 
recognition.      
 Both the diamino and xanthosine proximal fleximers 5 and 6 were also 
modeled in SAHase to determine the level of conformational flexibility in the context 
of an enzyme active site (Figure 46 and 47 on page 61).  Once again using automated  
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Figure 45.  Proximal and distal guanosine and isoguanosine fleximers in SAHase. 
 
molecular docking (InsightII, Discover from Accelrys), Monte Carlo simulation, 
followed by simulated annealing revealed that these proximal fleximers had a binding 
energies of –24.63 and –32.86 kcal/mol respectively.  To our surprise, both fleximers  
 
Table 3.  Binding Energy values for Proximal and distal guanosine and 
isoguanosine fleximers. 
 
FLEXIMER COLOR ∆G (KCAL/MOL) 
Distal Guanosine Orange –33.20 
Proximal Guanosine Purple –38.56 
Distal Isoguanosine Green –53.79 




Figure 46.  Proximal diamino fleximer in SAHase. 
 
 
Figure 47.  Proximal xanthosine fleximer in SAHase. 
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provided similar hydrogen bonding patterns with SAHase as was seen in Borchardt’s 
inhibitor.  Upon further analysis, both fleximers 5 and 6 did not maintain the 
necessary His353 to imidazole stacking interactions and the hydrogen bonding was 
slightly skewed – the sugar was binding to regions where the heterocyclic base, in 
Borchardt’s inhibitor, was binding. 
 We also modeled both the proximal adenosine and inosine fleximers 1 and 2 
in SAHase to determine the level of conformational flexibility within the active site.  
Using the same modeling parameters, it was shown that the binding energies for 1 
and 2 were –30.59 and –36.67 kcal/mol respectively.  The proximal adenosine 




Figure 48.  Proximal adenosine fleximer in SAHase. 
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with Borchardt’s inhibitor.  The heterocyclic base moiety, in both the fleximer and 
the inhibitor, showed hydrogen bonding patterns with His55 and Thr57.  Furthermore, 
the sugar moiety showed similar pattern binding with Lys186, however, the proximal 
adenosine had many more interactions with SAHase.  Even though the proximal 
inosine (as shown in Figure 49) had a “better” binding energy than both proximal 
adenosine and Borchardt’s inhibitor, as expected, the hydrogen bonding pattern was 




Figure 49.  Proximal inosine fleximer in SAHase. 
  
 While we cannot be certain that the theoretical conformation adopted by all of 
these distal and proximal fleximers in the modeling studies will prove to be real once 
co-crystallized with SAHase, it still provides rationale for the synthesis of these 
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potential inhibitors of SAHase.  If these fleximers indeed assemble within the active 
site of SAHase, as the modeling data suggests, it will provide valuable insight into the 



























 The nontrivial synthetic pathway that was required, since an organometallic 
cross-coupling approach would have mandated for a C-6 functionalized pyrimidine 
which is position to functionalize, for formation of the distal fleximers involved the 
formation of a tricyclic purine based nucleoside with a thiophene spacer ring followed 
by desulfurization to obtain the “split” purine nucleoside (Scheme 3).115  As a result 
of the tedious nature of this approach, we turned our attention to a variety of 
transition metal catalyzed cross coupling reactions to synthesize the proximal 
fleximers. 
 




 Our initial plan for the synthesis of the series of proximal fleximers involved 
conversion of benzyl protected 4-haloimidazole (13a or 13b), which was readily 
available from 4,5-dihaloimidazole (9a or 9b) as shown in Scheme 4,115,119  into its 
subsequent 4-metalloimidazole.  This would allow its use as a component in a variety 
of palladium catalyzed cross coupling methods.120  By utilizing a variety of 
substituted pyrimidine analogues, we postulated that strategic manipulation of the 
functional groups on the pyrimidine moiety would afford most of the desired 
proximal fleximers.   
 







 The synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-(4-bromoimidazol-3-
yl)-1-β-D-ribofuranose (13a) was obtained in 6 steps by starting with inexpensive, 
commercially available imidazole (7).  As shown in Scheme 5, treatment of 8 with 
bromine, glacial acetic acid and sodium acetate produced 2,4,5-tribromoimidazole (8) 
in 75% yield.121  Since the C-2 position is the most reactive towards nucleophilic 
substitution, treatment of 2,4,5-tribromoimidazole (9) with 2.5 equivalents of 
ethylmagnesium bromide in refluxing diethyl ether followed by NH4Cl afforded 4,5-





Reaction conditions:  a) Br2, AcOH, NaOAc; b) i) EtMgBr, Et2O, ii) NH4Cl; c) i) 
BSA, 1,2,3,5-O-tetraacetate--D-ribofuranose, CH3CN, ii) TMSOTf, 60 ºC, 18 h. 
 
Since 4,5-dibromoimidazole is a symmetric molecule, Vorbruggen coupling of 9a, at 
either N-1 or N-3, with 1,2,3,5-O-tetraacetate--D-ribofuranose resulted in only the 
nucleoside 10a.123  Vorbruggen coupling involved the reaction of persilylated 
heterocyclic moiety with peracylated sugars in the presence of a Lewis acid catalyst 
such as SnCl4 or trimethylsilyl triflate (TMSOTf).
124  Silylation of 4,5-
dibromoimidazole was achieved with N,O-bis(trimethylsilyl) acetamide (BSA) rather 
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than the more traditional hexamethyldisilazane due to difficulties in removing the 
excess HMDS, which, if still present in the reaction mixture, can inactivate the 
catalyst (Scheme 6).  The mechanism of the Vorbruggen coupling method first 
involves the conversion of the peracylated sugar into the stable 1,2-acyloxonium salt 
by both (i) anchimeric assistance of the 2’-acetate group and (ii) a Lewis acid, 
TMSOTf.  The resulting triflate anion reacts with the persilylated dibromoimidazole 
base, to regenerate TMSOTf, along with the simultaneous attack of the  face of the 
electrophilic “ribofuranose cation” to afford only the -nucleoside 10a (Scheme 7 on 
the next page).  
 




 Since the acetate groups would be susceptible to attack by future reaction 
conditions, specifically Grignard reagents, the acetate groups were removed with 
saturated methanolic ammonia at 100 ºC for 18 hours to afford triol 11a in 75% yield.  
However, the workup was tedious, so this, combined with the less than satisfactory 
yield prompted us to look for another procedure.  Employing another literature 
procedure, which used NH4OH in 95% ethanol at room temperature overnight, 
produced 11a quantitatively (Scheme 8 on the next page).115 
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Reaction conditions:  a) NH4OH, EtOH. 
 
 The hydroxyl groups were then reprotected as benzyl ethers since they should 
be stable to all the reaction conditions in the synthetic pathway.  Standard benzylation 
conditions of NaH followed by BnBr, however, resulted in incomplete benzylation of 
the three hydroxyls of 11a.  Various combinations of mono- and di- benzylated 
products were formed, which could not be separated effectively.  As a result, we 
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turned our attention to use an in situ formation of benzyl iodide, from benzyl bromide 
and tetrabutylammonium iodide (TBAI), which proved to be superior to the more 
traditional route. The resulting modification produced 12a in excellent yield (85%) 
(Scheme 9).125 Because the order of reactivity towards nucleophilic substitution for 
N1 protected imidazole rings is C2 > C5 >> C4, 12a was treated with 






Reaction conditions:  a) i) NaH, THF, 0 ºC, 3 h ii) TBAI, BnBr; b) i) EtMgBr, Et2O, 
3h, ii) NH4Cl. 
 
 
We then turned our attention to conversion of the 4-bromoimidazole protected 
nucleoside 13a into the requisite 4-metalloimidazole so that it could act as a coupling 
partner for the various Pd catalyzed cross-coupling methods which include the Stille, 
Negishi, Kumada and Suzuki reactions.120 
 We initially chose to try the Stille reaction,126,127 as there were examples in the 
literature with imidazolylstannanes that had been obtained in reasonable 
yields.120,126,127  In some respects, Stille coupling offered forth several advantages that 
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made it an attractive choice; organostannanes are i) stable towards moisture and air, 
ii) readily prepared and purified, and iii) tolerate an assortment of functional groups 
including amines, hydroxyls, and amides.120,126,127  The only drawback for medicinal 
chemistry purposes however, is the unfortunate toxicity that is inherent with the use 
of tin.  Despite this, we decided the advantages outweighed the disadvantages, and we 
went ahead. 
The Stille reaction is a versatile palladium-catalyzed cross coupling reaction 
of organostannanes with organic halides, acetates or perfluorinated sulfonates lacking 
a sp3 hybridized -hydrogen.120,128,129  Mechanistically, the carbon-carbon bond 
forming reaction begins with the formation of the organopalladium complex by 
oxidative addition of the Pd(0) species to the aryl halide or triflate.  Although a Pd(II) 
complex can be used, it is reduced to its active Pd(0) form by either ligand 
dissociation or nucleophilic organostannane (Scheme 10).130  During the formation of 
the organopalladium intermediate, the Pd(0) is oxidized to Pd(II) and the carbon-
halide bond is cleaved and two new -bonds to palladium are formed.  The palladium 
complex must be coordinatively unsaturated for the oxidative addition to take 
place.131  The mechanism proposed for this reaction step is an SN2 mechanism, or a 
concerted insertion of the Pd(0)L2 into the carbon-halide bond.    Next, 
transmetalation, the rate limiting step in Stille couplings,120,127 occurs to form a 
biarylated palladium moiety.  This step involves transfer of an aryl group from an 
organostannane adduct to palladium complex.  Prior to reductive elimination, the 
trans spatial arrangement of the ligands, L, are rearranged into a cis geometry by 
assistance of either the solvent or a palladium halide species.  Finally, a reductive 
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elimination produces the cross coupling product and the Pd(0) complex is regenerated 
(Scheme 10).  The mechanism of reductive elimination has been proposed to proceed 




 Based on the mechanism of the Stille cross coupling reaction, we initially 
sought to convert the 4-bromoimidazole protected nucleoside 13a into its subsequent 
imidazolylstannane 14 by using either trimethyl- or tributyltin chloride along with a 
combination of organic bases such as n-butyllithium or ethylmagnesium bromide.132-
135 To our disappointment, the product isolated was the dehalogenated imidazole 
nucleoside 15, which, interestingly was obtained in excellent yield (Scheme 11 on the 
next page). 132-135  This was most likely due to the unfortunate, but unavoidable, 
humidity in our laboratories at the time, since the building was undergoing renovation 
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and was open to the environment during much of the day.  As a result, it was 
impossible to maintain a truly "dry" atmosphere, given our lack of access to an 
appropriate dry box.  Based on the failure of the aforementioned reaction, several 
attempts by altering the solvent from Et2O to THF to CH2Cl2 were attempted but 




Reactions Conditions: R3SnCl, in Et2O or THF or CH2Cl2 with a) n-BuLi or b) 
EtMgBr, >90%. 
 
 Based upon the low reactivity of 4-bromoimidazole protected nucleoside 13a, 
we postulated that replacing the bromine at the C-4 position of the imidazole ring 
with a better leaving group such as iodine might allow for effective oxidative 
addition, thereby leading to the cross-coupling products.120  Hence, we synthesized 
the analogous 4-iodoimidazole protected nucleoside 13b using similar synthetic 
methodology (Figure 50 on the next page).   This proved to be advantageous, since 
the workup and purification steps for the diiodoimidazole analogue were much less 




Figure 50. 4-Haloimidazole protected nucleosides. 
 
Synthesis began with replacement of the C-4 and C-5 hydrogens with iodine 
using a facile literature procedure to give 9b in 93% yield (Scheme 12).122,136 Next, 
coupling diiodoimidazole 9b as before with the commercially available tetraacetate-
protected ribofuranose using N,O-bis(trimethylsilyl)acetamide and 




Reaction conditions:  a) ICl, KCl; b) i) BSA, CH3CN, ii) TMSOTf, 60 ºC, 18 h; c) 
NH4OH, EtOH. 
 
As previously mentioned, replacement of the acetate blocking groups with a 
more robust protecting group was necessary, due to the various reaction conditions 
that would be encountered in subsequent steps that would not be tolerated by either an 
alcohol or ester functionality. Standard base-promoted removal of the acetates 
afforded 11b as a white crystalline solid in a 75% overall yield for the two steps.  
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Reprotection of the three hydroxyls with the in situ125 formation of benzyliodide, was 
then accomplished to give 12b in an 80% yield.  Displacement of the C-5 iodine 




Reaction conditions:  a) i) NaH, THF, 0 ºC, 3 h ii) TBAI, BnBr; b) i) EtMgBr, Et2O, 3 
h, ii) NH4Cl. 
 
 As shown in Scheme 14, we used similar reaction conditions, as were used in 
Scheme 11, 132-135 in an effort to convert the protected 4-iodoimidazole 13b into its 
subsequent imidazolylstannane 14.  Unfortunately the dehalogenated imidazole 




Reactions Conditions: R3SnCl, in Et2O or THF with a) n-BuLi or b) EtMgBr, >90%. 
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Based on the low yielding reactions encountered in the efforts to produce 14, 
we attempted to form the imidazolylstannane in situ using hexabutylditin and then 
subsequently coupling it to 5-iodopyrimidin-4-one (17) (Scheme 15) using a variety 
of palladium catalyst such as PdCl2(PPh3)2, PdCl2(dppf), Pd(PPh3)4 and Pd2(dba)3 in 




Reaction Conditions: a) I2, NaOH, H2O. 
 
Unfortunately, no formation of the desired cross-coupling product 18, the 
requisite intermediate needed for the synthesis of proximal fleximers, inosine 2 and 
adenosine 1 (Scheme 16 on the next page), could be detected.  We then turned our 
attention to the Kumada and Negishi cross-coupling methodology.139,140  Kumada 
coupling involves cross-coupling Grignard reagents with alkyl, vinyl or aryl halides 
or triflates under nickel or palladium catalysis.120  The advantage of this reaction is 
the direct coupling of the Grignard reagent, which avoids the need for additional 
reaction steps such as the conversion of the Grignard reagent to organotin or 
organozinc compounds.120  Furthermore, the reaction does not need to be heated at 
high or even moderate temperatures.  The reaction, however, is limited to halide 





Reaction Conditions: a) i) 13b with n-BuLi in Et2O and (Bu3Sn)2 then ii) 17 with: b)  
PdCl2(PPh3)2; c) PdCl2(dppf); d) Pd(PPh3)4; or e) Pd2(dba)3; to form 2 f) Pd/C, 
HCO2NH4, EtOH, reflux or to form 1 g) i) P2S5, pyridine, reflux; ii) MeI, K2CO3; iii) 
NH3, butanol, 160°C; iv) Pd, HCO2NH4, EtOH, reflux. 
 
 
 Negishi coupling is a very versatile palladium catalyzed cross-coupling 
reaction involving an organozinc species and an electrophile such as an organohalide 
or triflate.120,140,141  Negishi coupling has several advantages that made it an attractive 
choice; organozinc reagents are highly selective towards a variety of electrophiles, 
they are prepared relatively easily and are compatible with a variety of functional 
groups such as amines, nitriles, and amides.141  Organozinc compounds are prepared 
in situ via organic bases such as organolithium or Grignard based reagents.  As shown 
in Scheme 17 on the next page, the mechanism of the Negishi coupling is similar to 









As summarized in Scheme 18 on the next page, the Kumada and Negishi were 
some of the other cross-coupling methods tried.139,141,142   We attempted to couple a 
halouracil analogue with the C- 4 substituted metalloimidazole, formed in situ, to 
form the cross-coupling adduct 21. Unfortunately, all efforts to construct the C-4 
substituted scaffold proved fruitless.  We altered the nature of the halouracil 
derivative by synthesizing both 5-bromo-1,3-dimethyluracil (20a) and 5-iodo-1,3-
dimethyluracil (20b) from 5-bromouracil (19a) and 5-iodouracil (19b) respectively 





Reaction conditions: a) Me2SO4, NaOH, H2O; b) i) 13b with EtMgBr or ZnCl2 in 




Also, altering the choice of solvent (Et2O or THF), the reaction temperature, 
or the palladium catalyst such as PdCl2(PPh3)2, PdCl2(dppf), Pd(PPh3)4, or Pd2(dba)3 
failed to yield the desired intermediate 21,133,144 from which several of the target 
fleximers could be realized. The failure of the Negishi conditions were surprising, 
since Negishi coupling had been reported to work well with C-4 iodo-substituted 
imidazoles, and was more tolerant of sensitive functional groups than traditional 
Grignard and organolithium approaches. We speculated that it could have been due to 
the π-electron deficient nature of the dimethyluracil since literature precedence 
indicated that the formation of the nucleophilic imidazole moiety, both in situ and as 
an isolated intermediate. As a result, it appeared that the pyrimidine system was 
simply insufficiently activated to participate in the cross coupling. 
 As shown in Scheme 19 on the next page, we then proposed an alternate 
synthetic route to obtain the proximal fleximers by a Negishi cross-coupling reaction 
between an organozinc analogue of 13b, formed in situ, and 5-bromo-2,4-
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dimethylthiopyrimidine (27) (synthesized from uracil (22) in Scheme 20 on page 81) 




Reaction conditions: a) EtMgBr, Et2O, then ZnCl2, then 27, Pd(PPh3)4, CH2Cl2. 
 
Since, oxidative addition step involving organic halides, for example, Pd (0) is 
oxidized by two electrons to Pd (II), while organic halides are reduced by two 
electrons. So, electron withdrawing substituents on the organic halide moiety may be 
expected to accelerate the oxidative addition reaction.120 The same reasoning also 
predicts that electron donating substituents in the ligands on Pd would accelerate 
oxidative addition.  Speculation that the inherent electron deficient nature of the 
pyrimidine ring system was the cause for the significant lack of reactivity noted to 
date was a strong possibility.  If this was indeed true, it was clear that to be 
successful, the electronics of the pyrimidine ring system had to be enhanced, 
therefore electron donating substituents such as ethers or thioethers might prove to be 
a possible solution.  We chose to focus on the thioethers first, as their conversion to 







Reaction conditions: a) Br2, H2O; b) POCl3, DEA; c) S=C(NH2)2, anhydrous EtOH; 
d) NaOH; e) Me2SO4, NaOH. 
 
In order to synthesize 27 (Scheme 20), cheap, commercially available uracil 
(22) was readily converted to 5-bromouracil (23) using bromine and H2O.
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Subsequent chlorination of 23 with standard conditions provided 5-bromo-2,4- 
dichloropyrimidine (24) in 91% yield.147  Next, treatment with thiourea gave 25 in 
65% yield, which was then hydrolyzed to the dithiocarbonyl analogue 26 in 84% 
yield using sodium hydroxide.148,149  Finally, methylation with standard conditions 
gave 27 in a 76% yield. 
We postulated that by using standard ammonolysis conditions, subsequent 
desulfurization, and deprotection of the hydroxyls on cross-coupled intermediate 28 
would have formed proximal adenosine 1 (Scheme 21 on the next page).  
Unfortunately, upon Negishi coupling of 13b and 27 the only product that was 
formed was shown by NMR to be 29 (Scheme 19 on top of page 81), where coupling 
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to the imidazole had occurred at the C-4 of the pyrimidine, displacing the C-4 




Reaction Conditions: a) i) NH3, butanol, 160°C; ii) Raney Ni, MeOH, reflux; iii) Pd, 
HCO2NH4, EtOH, reflux. 
 
 
 After exhausting options with the Stille, Kumada and Negishi cross coupling 
reactions, we turned our attention to Suzuki-Murayama cross couplings.120,129,150  The 
Suzuki coupling involves palladium-catalyzed cross coupling between organoboronic 
acid reagents and organohalides (or triflates).120  Suzuki coupling reactions have three 
major advantages; one, they tolerate the presence of various functional groups in the 
coupling moieties, two, they are air and moisture stable making them relatively 
simple to handle, and three, they are non-toxic unlike the organotin compounds used 
in Stille cross coupling.120  Although there were some challenges associated with the 
synthesis of aryl boronic acid; since they require very low temperatures, as well as 
their tendency to cross couple with each other, we still pursued this synthetic pathway 
hoping to overcome these disadvantages. 
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Initially, we attempted to convert protected 4-iodoimidazole 13b into its 
analagous protected imidazolyl-4-boronic acid 30.150,151  Iodinated imidazole based 
nucleoside 13b was treated with either n-BuLi or EtMgBr in anhydrous THF or 
CH2Cl2 at –78 °C followed by the addition of a trialkyl borate, B(O
iPr)3 while 
maintaining the temperature at -78 °C.150,151   As shown in Scheme 22, these efforts 
proved futile as well, since all attempts once again resulted in formation of the 





Reaction Conditions: a) i) n-BuLi or EtMgBr, THF or CH2Cl2, -78 °C; ii) B(O
iPr)3; 
iii) aq. HCl. 
 
 
 Continuing the pursuit for the proximal fleximers via Suzuki coupling, we 
decided to form an aryl borate complex (which was not isolated) in situ by the 
addition of bis(pinacolato)diboron, KOAc, PdCl2(dppf) in DMF.
152,153  Upon 
formation of 31, 5-iodopyrimidin-4-one (17), PdCl2(dppf), and K2CO3 were added 
such that the proximal fleximer intermediate 18 would be realized and subsequently 
isolated.  Unfortunately, formation of 18 did not occur and only starting material 13b 





Reaction Conditions: a) bis(pinacolato)diboron, KOAc, PdCl2(dppf), DMF, 80 ºC, 2 
h; b) 17, PdCl2(dppf), K2CO3. 
 
At this point we reversed our strategy to employ the pyrimidine as the 
nucleophilic component.  Based on retrosynthetic analysis, we once again utilized 
palladium catalyzed cross-couplings such as Stille, Kumada, Negishi and Suzuki 
reactions (Scheme 24).  We attempted to couple 13b to a variety of organometallic 
pyrimidine species, including the pyrimidinylstannane 32 which was synthesized by 
first treating 5-iodouracil (19b) with sodium hydroxide in refluxing dimethyl sulfate 
to afford 5-iodo-1,3-dimethyluracil (20b).154  This was followed by heating 20b with 
hexabutylditin in toluene with PdCl2(PPh3)2 under Ar to yield 5-tri-n-butylstannyl-










Reaction Conditions: a) Me2SO4, NaOH, H2O; b) (Bu3Sn)2, PdCl2(PPh3)2, PhCH3. 
 
 
 Upon formation of the pyrimidinylstannane, we attempted to couple 32 to 13b 
using a variety of palladium reagents including; Pd(PPh3)4 and PdCl2(PPh3)2 in either 
DMF or 1,2-dimethoxyethane (DME) at 80 ºC (Scheme 26).143,155  Unfortunately, 
pyrimidinylstannane 32 failed to undergo coupling with 13b under standard Stille 
reaction conditions. 
 Although Stille cross-coupling reactions have higher chemoselectivity than 
their analogous Negishi cross-coupling reactions, organostannanes have been shown 
to be less reactive than organozinc compounds.120  Therefore, we sought out to 




Reaction conditions: a) 13b, Pd(PPh3)4, CuI, DMF or DME; b) 13b, PdCl2(PPh3)2, 
DMF or DME, 80 °C. 
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Using our previously synthesized 5-iodo-1,3-dimethyluracil (20b), we 
attempted to form 33 through the addition of EtMgBr or n-BuLi in ether or THF, 
followed by the addition of zinc (II) chloride (Scheme 27).  Attempts to couple the 
organozinc moiety 33 synthesized in situ with 13b using a variety of palladium 
reagents including; Pd(PPh3)4 and PdCl2(PPh3)2 in either DMF or DME at 80 ºC 





Reaction Conditions: a) i) EtMgBr or n-BuLi, Et2O or THF; ii) ZnCl2; b) 13b, 
Pd(PPh3)4, CuI, DMF or DME; c) 13b, PdCl2(PPh3)2, DMF or DME, 80 °C. 
 
We postulated that the organozinc chloride complex 33 did not form 
effectively, therefore we attempted to insert Zn between the C-I bond, by heating 5-
iodo-1,3-dimethyluracil (20b) with activated zinc powder, to form the organozinc 
iodide adduct 34 in situ.140,156  Once again as shown in Scheme 28 on the next page, 
attempts to couple the 13b to 34 synthesized using a variety of palladium reagents 






Reaction Conditions: a) Zn powder, N,N-dimethylacetamide, heat; b) 13b, Pd(PPh3)4, 
CuI, DMF or DME; c) 13b, PdCl2(PPh3)2, DMF or DME, 80 °C. 
 
 Moving next to the Suzuki coupling, we sought to synthesize our boronic acid 
coupling partner 36.  Using an in situ formation of sodium benzoate, from NaH and 
benzyl alcohol, we converted 5-bromo-2,4-dichloropyrimidine (24) into its analogous 
dibenzyloxy ether pyrimidine system 35 in 91% yield.157  Sequential treatment of 5-
bromo-2,4-dibenzyloxypyrimidine (35) with n-BuLi, triisopropyl borate, followed by 
aqueous HCl afforded the aryl boronic acid 36, albeit in low yield (22%) (Scheme 
29).151 Attempts to increase the yield of 36, either by (i) lowering temperatures to aid 
in formation of the boronic acid or (ii) adding molecular sieves to remove any trace 





Reaction Conditions: a) NaH, BnOH, PhCH3; b) i) n-BuLi, THF, -78 °C, ii) B(O
iPr)3; 
iii) aq. HCl or c) i)B(OiPr)3, THF, PhCH3, -78 °C, ii) n-BuLi, iii) aq. HCl. 
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 Eventually, a procedure outlined by Schinazi and Prusoff showed that slow, 
dropwise addition of n-BuLi to an aryl halide and alkyl borate provided excellent 
yields.157  We implemented this protocol to a solution containing 5-bromo-2,4-
dibenzyloxy-pyrimidine (35) and triisopropyl borate in THF:toluene (1:4 volume 
ratio) at –78 °C and slowly added n-BuLi dropwise.  Upon quenching the reaction 
with aqueous HCl, we obtained 5-(dihydroxyboryl)-2,4-bis(benzyloxy)pyrimidine 
(36) in exceptional yield (95%).157 
Coupling was then successfully carried out with tetrakis (triphenylphosphine) 
palladium (0) in refluxing DME and saturated aqueous NaHCO3 to give 37 (67%) 
(Scheme 30).158  Removal of all five of the benzyl groups with palladium on carbon, 
ammonium formate in EtOH was accomplished in 88% yield to give the proximal 




Reaction Conditions: a) Pd(PPh3)4, DME, NaHCO3, reflux, 4h. 
 
 Using the proximal xanthosine fleximer 6, we postulated that both the 
guanosine and isoguanosine fleximers 3 and 4 could be readily obtained.  In order to 
form the proximal isoguanosine 4, we attempted to directly convert the C-4 oxo 
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moiety into the free amino group via a literature procedure by Selway et al160 which 
showed that a uridine analogue was readily converted into its cytidine analogue in 
excellent yields.   
Scheme 31 
 
Reaction Conditions: a) Pd/C, HCO2NH4, EtOH, reflux. 
 
Therefore, treatment of the xanthosine fleximer 6 with hexamethyldisilazane, 
formamidine and ammonium sulfate was heated in a Parr bomb for 72 hours (Scheme 
32).160  Unfortunately, our analogous reaction did not provide us with the proximal 
isoguanosine 4.   
Scheme 32 
 
Reaction Conditions: a) HMDS, formamidine, (NH4)2SO4, 120 °C, 72 h. 
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We turned our attention to the synthesis of the proximal guanosine fleximer 3 
(from xanthosine fleximer 6) using a procedure outlined by Watanabe et al which 
presented the analogous conversion of -uridine into -isocytidine (Scheme 33).161  
Treatment of -uridine with dimethylformamide dimethylacetal provided the 
methylated -uridine which was then subsequently treated with guanidine to afford 
-isocytidine in excellent yield.  Therefore, we used our analogous -uridine system, 
proximal xanthosine fleximer 6 and alkylated the pyrimidine moiety to yield 38.161  
Attempting to convert the “urea” moiety in the pyrimidine ring, with guanidine, into 




          -uridine             -isocytidine 
Reaction Conditions: a) (CH3)2NCH(OCH3)2; b) guanidine. 
 
 Alternatively, we attempted to obtain the proximal guanosine and 
isoguanosine fleximers (3 and 4) by selectively treatment of proximal diamino 
fleximer 5.  Based on literature precedence162 for the conversion of a 2,4-
diaminopurine based nucleoside into either a 2-amino-4-oxopurine or 4-amino-2-





Reaction Conditions: a) (CH3)2NCH(OCH3)2; b) NaOEt, guanidine. 
 
Therefore, treatment of 37 with ammonia in ethanol at 160 °C for 96 hours in 
a steel Parr bomb afforded 39 in albeit moderate yield (40%),162 which, following by 





Reaction Conditions: a) NH3, EtOH, 160 °C, 96 h; b) Pd/C, HCO2NH4, EtOH, reflux. 
 
With the first two proximal fleximers finally in hand, the remaining goal was 
to manipulate the diamino fleximer 5 to give us the guanosine and isoguanosine 
fleximers (3 and 4 respectively) we had initially set our sights on.  The proximal 
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isoguanosine fleximer 4 was realized following selective conversion of the C-2 amino 
group of the protected diamino fleximer 39 to the desired carbonyl using typical 
diazotization conditions, and subsequent deblocking of the benzyl protecting groups 
with Pd/C and ammonium formate in refluxing ethanol (41% yield, two steps from 
39) (Scheme 36).162  Finally, the diamino fleximer 5 was converted directly to 3 using 









After accomplishing the formation of the proximal fleximers; guanosine, 
isoguanosine, diamino-, and xanthosine 3-6 respectively, we revisited the synthesis of 
the proximal adenosine and inosine fleximers 1 and 2.  Based on our previous success 
of the Suzuki coupling, we wanted to implement similar reaction conditions on an 
analogous imidazole and pyrimidine moiety.  With this in mind, we coupled 
commercially available 5-(dihydroxyboryl)pyrimidine (41) to the previously 












Reaction Conditions: a) PdCl2(dppf), K2CO3, THF, 60 °C, 18 h. 
 
While this initially appeared successful, since the coupling produced 42 in a 
66% yield, attempts to form 43 using dissolving metal chemistry, specifically KNH2 
and NH3, followed by strong oxidizing conditions using KMnO4 resulted in 
decomposition of the starting materials (Scheme 39 on the next page).164 
 At this point we turned to construction of the heterocyclic moieties by means 
of linear approach. Starting with commercially available histidine hydrochloride (44), 
treatment with commercially available sodium hypochlorite (household bleach)165 
afforded 45 in a 70% yield (Scheme 40).  This particular reaction proved to be erratic 
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in nature, as all attempts with a variety of generic brands of bleach resulted in low to 











Reaction Conditions: a) NaOCl, H2O. 
 
Upon closer inspection, reasons for this irregular behavior became obvious; 
the Clorox bleach had a higher percentage of sodium hypochlorite per bottle than the 
generic brands. More importantly, the Clorox bleach contains none of the common 
stabilizers found in the generic brands. These stabilizers likely interfere with product 







Once 45 was in hand, standard nucleoside coupling to commercially available 
1,2,3,5-O-tetraacetate--D-ribofuranose with N,O-bis(trimethylsilyl)acetamide and 
trimethylsilyltriflate was accomplished, albeit in less than desirable yields (36%),166 
to give 46a. This low yield was due to the formation of both possible coupling 
products, the 1,4- and 1,5-disubstituted imidazoles (46a and 46b), which were readily 
separated by column chromatography (Scheme 42 on the next page). Literature has 
shown that by 1H NMR analysis it is possible to distinguish between the two 
products. The characteristic downfield shift of the H-5 proton as compared to the shift 
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for H-2 is indicative of the 1,4-disubsituted imidazole, whereas for the 1,5-





Reaction Conditions: a) i) 1,2,3,5-O-tetraacetate--D-ribofuranose, BSA, CH3CN, 4 
h, ii) TMSOTf, 60 °C, 18 h. 
 
 Subsequent inverse electron demand Diels-Alder reaction of nucleoside 46a 
with commercially available 1,3,5-triazine (47) provided the amino substituted 
pyrimidine ring with concurrent deblocking of the acetate protecting group albeit in 
less than desirable yields (15%) (Scheme 43 on the next page).168-170  The reaction 
proceeds via an in situ nitrile to a substituted ene-imine tautomerization [4 + 2] 
cycloaddition with 1,3,5-triazine to afford the bicyclic adduct 48.  Nucleophilic 
addition of sodium methoxide to the endocyclic imine as well as concurrent 
deblocking of the acetate protecting group provided 49. Finally, the bicyclic 
intermediate 49 underwent a retro Diels-Alder reaction, resulting in a loss of methyl 
formimidate, and subsequent formation of the proximal adenosine 1 (Scheme 44 on 
page 99).  Although these reactions which produced proximal adenosine 1 were 
relatively low yielding, the final target was obtained in a 3.8% overall yield in only 3 





Reaction Conditions: a) NaOMe, MeOH, reflux. 
 
 Inosine fleximer 2 was then realized from 1 using standard diazotization 
conditions, to give 2 in 68% yield (Scheme 45 on the next page).162 While admittedly 
the yields for these steps are not optimal, it is notable that the overall yield is 
comparable to the typical yields obtained for other modified nucleosides, since 1 (and 
subsequently, 2) are possible in only three (or four) steps using cheap, commercially 
available materials. As a result, while we will continue to optimize these yields, we 
feel this is not a hindrance to using this route. 
 With the proximal fleximers 1-6 now in hand, we can proceed with our 
investigations into exploring the confines of biologically significant enzymes. By 
comparing the results already obtained with the distal fleximers, it will be possible to 
see if altering the position of the fleximer bond has a significant effect on recognition 










Reaction Conditions: a) NaNO2, AcOH, H2O. 
 
 In summary, a series of traditional cross coupling methods using a variety of 
catalysts and conditions were explored to realize the synthesis of the second series of 
fleximers. It is clear from the efforts outlined herein that the imidazole and 
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pyrimidine ring systems are recalcitrant at best and that work remains to fully 
understand the ideal conditions to manipulate these heterocycles more efficiently. We 
are, however, encouraged by the reasonably good results finally obtained with the 






 It will be necessary to investigate the consequences of flexibility for enzyme 
recognition and inhibition.  First, inhibition assays for SAHase will need to be done 
by Dr. Sunny Zhou at Washington State University.  As previously mentioned, 
SAHase catalyzes the reversible transformation from SAH to homocysteine (Hcy) 
and adenosine (Ado).  The equilibrium constant (Keq) is about 1 M, favoring, the 
synthetic direction.  For instance, if 100 M SAH is incubated with SAHase, only 
about 10% of product conversion is expected when equilibrium is reached (final 
concentration of Hcy and Ado is 9.5 M).  Under physiological conditions, however, 
the net reaction proceeds in the hydrolysis direction, as the hydrolysis products are 
rapidly depleted via several metabolic pathways.  Ado is metabolized by adenosine 
deaminase (ADA) and adenosine kinase, and Hcy is used for cysteine and methionine 
biosynthesis. 
 ADA is used to shift the overall equilibrium to the hydrolysis direction in a 
continuous photometric SAHase assay (as shown in Scheme 46 on the next page).  
ADA irreversibly converts the adenosine product into inosine which is associated 
with a decrease of absorption at 265 nm with a change of the extinction coefficient of 
8,100 M-1 cm-1.85,171  This method will be used for the initial inhibitor screening.  
Another commonly used assay is based on the quantification of Hcy, the other 
hydrolysis product.  As shown in Scheme 47 on the next page, the Hcy product is 
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then reacted with 5,5’-dithiobis-2-nitrobenzoic acid (DTNB, Ellman’s reagent) to 










determined from the absorption changes at 412 nm due to TNB, using an extinction 
coefficient of 13,700 M-1 cm-1.172  Since the fleximers 1-6 do not absorb around 410 
nm, the sensitivity of the assay will not be affected by inhibitor concentrations. 
 Because reactions catalyzed by SAHase are reversible and involve multiple 
steps, it might be desirable to characterize enzyme inhibition in the synthetic 
direction.  There is, however, no reported continuous activity assay for SAHase in the 
synthetic direction.  There are however, assays based on HPLC analysis of the SAH 
product and the Hcy and Ado substrates.  However, the process is tedious and time 
consuming.  More importantly, since the reaction is reversible, accumulation of SAH 
complicates kinetic analysis.  Our collaborators have developed an enzyme-coupled 






In this assay, SAH formed in the synthetic direction is cleaved into adenine 
and S-ribosyl-homocysteine by SAH nucleosidase and the adenine intermediate is 
subsequently converted into hypoxanthine in the presence of ADA.173,174  The latter 
transformation is associated with an absorption decrease at 265 nm with a change of 
extinction coefficient of ~8,000 M-1 cm-1, similar to the reaction catalyzed by ADA 
currently used for the hydrolysis assay.  Again, absorption changes at 265 nm can be 
conveniently monitored in a microplate format on a UV-visible microplate reader.  
Furthermore, since SAH nucleosidase irreversibly cleaves SAH, no SAH product is 
built up using this enzyme-coupled assay, thereby simplifying the kinetic analysis.   
 
X-Ray Crystallography 
 Using recombinant human SAHase for the crystallization experiments will be 
eventually purified from cell-free extracts of E. coli transformed with the plasmid 
pPROKcd20.  It will be necessary to obtain a pure NAD+ form of the enzyme, such 
that incubation with the fleximers 1-6 (Figure 51 on the next page) can readily occur.   
Followings the structure determination and refinement of the various fleximer 
complexes, an analysis of the structures will be performed to identify any 
conformational changes that may result from the presence of the specific inhibitor.  It 
is hoped that these structurally unique nucleosides will provide critical information 















 Since the fleximers represent an entirely new class of potential SAHase and 
antiviral inhibitors as yet uncharacterized, fleximers 1-6 (Figure 51 on the previous 
page) have provided us a strong basis set for comparison with later analogues.  Given 
the potent biological activity exhibited by 3-deazaadenosine analogues,13 the next 
rational step is the synthesis of proximal 3-deazaadenosine fleximer (Figure 52). 
 
 
Figure 52.  Proximal 3-deazaadenosine fleximer. 
 
Due to the extremely potent biological activity exhibited by the carbocyclic 
aristeromycin and Neplanocin A analogues,96,97 the carbocyclic fleximers, also 
present logical targets.  Furthermore, due to the cytotoxicity of the Ari and NpcA 
analogues (since they can easily be phosphorylated and thus resemble ATP),96,97 it 
would be interesting to synthesize the subsequent 4’,5’-tetrahydro and 4’,5’-
unsaturated derivatives (Figure 53 on the next page).  As previously mentioned, both 
of these analogues were shown to irreversibly inhibit SAHase and more significantly, 





Figure 53.  Carbocylic proximal adenosine fleximers. 
 
Hence, given the antiviral and SAHase activity of carbocyclic nucleosides 
along with the potential for overcoming resistance mechanisms by incorporations of 
flexibility that is inherent in the fleximers, it is hoped that these two leads may 







Modeling.  All potential inhibitors were docked into the SAHase crystal 
structure (PDB 1A7A) and calculations performed on a SGI Octane2 using Accelrys® 
InsightII/Discover with a CFF forcefield, which is derived from ab initio calculations 
on the Hartree-Fock level of theory using the 6-311G* basis set. The inhibitors were 
optimized using steepest descent calculations. Then using Monte Carlo techniques, up 
to twenty spatial conformers were generated for each inhibitor. The ten lowest energy 
conformations were then minimized using simulated annealing techniques. The final 
structures were analyzed for the best ligand structure with the lowest energy value. 
The nonessential hydrogens have been removed for clarity.  
 
General.  Melting points were recorded on a Meltemp II melting point 
apparatus and are uncorrected. Combustion analyses were performed by Atlantic 
Microlabs, Inc., Atlanta, GA. 1H and 13C NMR spectra were recorded on a Bruker 
300 spectrometer (operated at 400 and 100 MHz, respectively) all referenced to 
internal tetramethylsilane (TMS) at 0.0 ppm. The spin multiplicities are indicated by 
the symbols s (singlet), d (doublet), t (triplet), m (multiplet) and b (broad). UV-vis 
activity was measured on a Shimadzu 1601 UV/Vis spectrophotometer. Reactions 
were monitored by thin-layer chromatography (TLC) using 0.25-mm Whatman 
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Diamond silica gel 60-F254 precoated plates with visualization by irradiation with a 
Mineralight UVGL-25 lamp. Column chromatography was performed on Whatman 
silica, 200-400 mesh, 60 Å, and elution with the indicated solvent system. HPLC 
purification was carried out on a Hewlet- Packard 1090 liquid chromatograph. Yields 





  Bromine (100 g, 0.625 mol) in glacial acetic acid 
(200 mL) was added during 1 h to a stirred suspension of imidazole 7 (13.6 g, 0.200 
mol) and anhydrous sodium acetate (200 g) in acetic acid (1.0 L). When 
approximately one-third of bromine/acetic acid mixture had been consumed, 
additional sodium acetate (50 g) was added to the suspension. Stirring continued for 
18 h and the solvent was removed under reduced pressure. H2O (4 L) was added to 
the residue and the mixture was filtered. The precipitate was washed with excess 
amount of H2O (2.0 L) to give a white powder (45.7 g, 75%), mp: 220-222 °C (from 
Aldrich: 217-220 °C). 
 
4,5-dibromoimidazole (9a).
115,122 EtMgBr (3.0 M in ethyl ether, 83.3 mL, 0.250 mol) 
was added dropwise to a suspension of 2,4,5-tribromoimidazole (8) (30.5 g, 0.100 
mol) in anhydrous ethyl ether (1 L) at 0 °C. Then the mixture was heated under gentle 
reflux for 18 h.  The solvent was removed under reduced pressure and subsequently 
saturated aqueous NH4Cl (500 mL) was slowly added to the residue. The mixture was 
extracted with ethyl acetate (3 x 300 mL). The organic extracts were combined, 
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washed with brine (600 mL), dried over MgSO4, and the solvent was removed under 
reduced pressure to give a light brown powder. Recrystallization in hot ethyl acetate 
gave the titled compound as a white crystalline solid (19.4 g, 86%), mp: 223-226 °C. 




 An aqueous solution (500 mL) of imidazole (30.0 g, 
0.441 mol) was added dropwise to a solution of KICl2 (2.0 M, 550 mL, 1.1 mol, 
prepared from dissolving ICl (79.9 g, 1.03 mol) in an aqueous solution of KCl (131.5 
g, 1.77 mol in 550 mL of H2O) at rt. The mixture was stirred for an additional 10 h, 
followed by slow addition of 2M NaOH solution until the suspension was completely 
dissolved. The clear solution was then acidified to pH 9.50 by dropwise addition of 
concentrated HCl. The resulting product was filtered to afford an off-white powder, 
which, following recrystallization in EtOH, gave 9b as a white crystalline solid 
(131.2 g, 93%), mp 188-191 °C.  1H NMR (DMSO-d6) δ 7.76 (s, 1 H); 
13C NMR 





  To a stirred solution of 1,2,3,5-O-tetraacetate--D-ribofuranose (16.0 g, 
50 mmol) and 4,5-dibromoimidazole (9a) (11.3 g, 50 mmol) in anhydrous acetonitrile 
(500 mL) was added N,O-bis(trimethylsilyl)acetamide (BSA) (48.7 mL, 0.20 mol). 
The reaction mixture was stirred for 3 h at room temperature and cooled to 0 °C, at 
which point, trimethylsilyl trifluoromethylsulfonate (TMSOTf) (10.7 mL, 56 mmol) 
was slowly added. The mixture was further stirred at 60 °C for 18 h.  The solution 
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was cooled to room temperature and the solvent was removed to produce a brown 
syrup.  The residue was then chilled to 0 °C, and saturated aqueous NaHCO3 solution 
(400 mL) was slowly added. The mixture was extracted with CH2Cl2 (3 x 250 mL). 
The organic extracts were combined, washed with brine (250 mL), dried over 
MgSO4. Then the solvent was removed under reduced pressure to give a brown syrup. 
Column chromatography eluting with petroleum ether:EtOAc (1:1) gave 10a as a pale 
yellow syrup (17.4 g, 70%), which was used directly in the next step: 1H NMR 
(CDCl3) δ 2.06 (s, 9 H), 4.25-4.30 (m, 2 H), 4.33-4.38 (m, 1 H), 5.31 (dt, 2.7 Hz, 5.2 
Hz, 1 H), 5.46 (dd, 2.2 Hz, 5.2 Hz, 1 H), 5.77 (dd, 2.6 Hz, 4.6 Hz, 1 H), 7.76 (s, 1 H); 
13C NMR (CDCl3) δ 20.2, 20.3, 20.5, 62.3, 69.6, 73.5, 80.0, 88.0, 102.4, 118.2, 135.2, 




115,123 N,O-bis(trimethylsilyl)acetamide (BSA) (73.9 mL, 0.30 mol) was added 
to a stirred solution of 9b (50.0 g, 156 mmol) and 1,2,3,5-tetra-O-acetate-β-D-
ribofuranose (50.0 g, 157 mmol) in anhydrous acetonitrile (500 mL). The mixture 
was stirred for an additional 4 h at rt under Ar. The solution was then cooled to 0°C, 
at which point trimethylsilyl trifluromethylsulfonate (TMSOTf) (31 mL, 172 mmol) 
was added dropwise. The mixture was heated at 60°C under Ar for 18 h. The solvent 
was removed under reduced pressure and the resulting residue was cooled to 0°C, 
followed by portionwise addition of aqueous NaHCO3 until production of gas ceased. 
The mixture was extracted with CH2Cl2 (3 x 400 mL), the organic extracts combined, 
washed with brine (2 x 300 mL), dried over MgSO4, and the solvent removed under 
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reduced pressure to give 10b as a light brown syrup (67.6 g), which was used without 
further purification.  
 
(4,5-Dibromoimidazol-3-yl)-1--D-ribofuranose (11a).
115 A solution of 2,3-
diacetoxy-5-acetoxymethyl-1-(4,5-dibromoimidazol-3-yl)--D-ribofuranose (10a) 
(13.7 g, 28.3 mmol) and concentrated aqueous ammonium hydroxide (28%, 300 mL) 
in ethanol (250 mL) was stirred at room temperature for 18 h. Then the solvent 
removed under reduced pressure to afford a light brown foam. Column 
chromatography eluting with CHCl3:MeOH (9:1) gave 11a as a colorless syrup (10.1 
g, quantitative): 1H NMR (CD3OD) δ 3.72 (dd, 3.2 Hz, 12.2 Hz, 1 H), 3.84 (dd, 3.0 
Hz, 12.2 Hz, 1 H), 4.03-4.07 (m, 1 H), 4.22 (t, 5.1 Hz, 1 H), 4.32 (t, 4.8 Hz, 1 H), 
5.69 (d, 4.5 Hz, 1 H), 8.24 (s, 1 H); 13C NMR (CD3OD) δ 61.9, 71.0, 76.8, 86.6, 92.4, 
104.3, 117.5, 138.1. Anal. Calcd for C8H10Br2N2O4·0.25MeOH: C, 27.05; H, 3.02; N, 
7.64; Br, 43.68. Found: C, 26.99; H, 2.83; N, 7.62; Br, 43.57.  
 
(4,5-Diiodoimidazol-3-yl)-1-β-D-ribofuranose (11b).115 A mixture of crude 10b 
(67.6 g, 0.117 mol) and concentrated ammonium hydroxide (28%, 500 mL) in EtOH 
(300 mL) was stirred at rt for 18 h.  The resulting precipitate was filtered and washed 
with cold H2O to afford 11b as a white crystalline solid (52.8 g, 75% for 2 steps). 
1H 
NMR (DMSO-d6) δ 3.49 (dd, 3.9 Hz, 12.0 Hz, 1 H), 3.57 (dd, 3.9 Hz, 12.0 Hz, 1 H), 
3.88 (q, 3.6 Hz, 1 H), 4.01 (t, 3.6 Hz, 1 H), 4.24 (t, 5.0 Hz, 1 H), 5.19 (t, 5.1 Hz, 1 H), 
5.33 (d, 4.8 Hz, 1 H), 5.46 (d, 5.1 Hz, 1 H), 5.60 (d, 6.3 Hz, 1 H), 8.15 (s, 1 H). 13C 




125  Sodium hydride (95%, 2.9 g, 0.115 mol) was added to a 
stirred solution of 11a (13.7 g, 38.3 mmol) in anhydrous THF (100 mL) at 0 °C under 
Ar. The mixture was then stirred at room temperature for 3 h. Next, 
tetrabutylammonium iodide (0.5 g, 1.35 mmol) was added followed by benzyl 
bromide (19.7 g, 0.115 mol).  The mixture was stirred at room temperature for 3 h, 
followed by quenching with ethanol (50 mL). The solvent was removed under 
reduced pressure; saturated NH4Cl solution (200 mL) was added and the mixture 
extracted with CH2Cl2 (3 x 200 mL). The organic extracts were combined, washed 
with brine (200 mL), and dried over MgSO4. The solvent was removed under reduced 
pressure to provide a pale brown syrup. Column chromatography eluting with 
hexane:ethyl acetate (3:1) gave 12a as a colorless crystalline solid (20.4 g, 85% 
yield), mp 86-88 °C: 1H NMR (CDCl3) δ 3.54 (dd, 2.4 Hz, 10.8 Hz, 1 H), 3.75 (dd, 
2.7 Hz, 10.8 Hz, 1 H), 4.10-4.16 (m, 2 H), 4.31-4.34 (m, 1 H), 4.43-4.66 (m, 6 H), 
5.83 (d, 3.3 Hz, 1 H), 7.22-7.38 (m, 15 H), 7.88 (s, 1 H); 13C NMR (CDCl3) δ 68.3, 
72.5, 72.6, 73.5, 75.5, 80.5, 81.9, 89.5, 101.8, 117.6, 127.8, 127.9, 128.0, 128.2, 
128.5, 128.6, 136.2, 136.7, 137.1. Anal. Calcd for C29H28Br2N2O4: C, 55.43; H, 4.49; 





 To a stirred solution of 11b (21.0 g, 45.9 mmol) in anhydrous 
THF (300 mL) at 0°C was added NaH (95% dry, 4.06 g, 161 mmol) in small portions 
over a period of 10 minutes. The resulting mixture was stirred at rt for 3 h, at which 
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point, tetrabutylammonium iodide (3.4 g, 9.20 mmol) was added, followed by 
dropwise addition of benzyl bromide (19.1 mL, 161 mmol). The new mixture was 
stirred at rt for 18 h. The solvent was then removed under reduced pressure, and 
saturated aqueous NH4Cl solution (200 mL) added to the residue. The mixture was 
extracted with CH2Cl2 (3 x 250 mL), the organic extracts combined, washed with 
brine (2 x 300 mL), dried over MgSO4, and the solvent removed under reduced 
pressure to give a yellow syrup. Column chromatography eluting with hexane:EtOAc 
(3:1) gave 12b as a white crystalline solid (26.5 g, 80% yield), mp 86-88 °C. 1H 
NMR (CDCl3) δ 3.53 (dd, 2.5 Hz, 10.8 Hz, 1 H), 3.75 (dd, 2.4 Hz, 10.8 Hz, 1 H), 
4.08-4.18 (m, 2 H), 4.31-4.34 (m, 1 H), 4.44-4.70 (m, 6 H), 5.82 (d, 3.6 Hz, 1 H), 
7.21-7.37 (m, 15 H), 7.99 (s, 1 H). 13C NMR (CDCl3) δ 66.3, 72.6, 72.9, 73.5, 75.7, 
79.8, 80.9, 81.9, 92.0, 127.8, 127.9, 128.2, 128.5, 128.6, 136.9, 137.2, 140.3. Anal. 
Calcd for C29H28I2N2O4: C, 48.22; H, 3.91; N, 3.88; I, 35.14. Found: C, 48.48; H, 




119  EtMgBr (3.0 M, 19 mL, 57 mmol) was added dropwise to a 
solution of 12a (34.7 g, 48.0 mmol) in anhydrous ether (500 mL) at room 
temperature. The mixture was further stirred at room temperature for 3 h. Anhydrous 
ethanol (50 mL) was added to quench the reaction mixture.  The solvent was then 
removed under reduced pressure and the residue was cooled to 0 °C.  Saturated 
aqueous NH4Cl solution (300 mL) was added and the mixture was extracted with 
CH2Cl2 (3 x 200 mL).  The organic extracts were combined, washed with brine (400 
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mL), dried over MgSO4, and the solvent was removed under reduced pressure to give 
a colorless syrup.  Column chromatography eluting with hexane:ethyl acetate  (2:1) 
gave 13a as a colorless syrup (23.6 g, 82%). 1H NMR (CDCl3) δ 3.51 (dd, 2.4 Hz, 
10.8 Hz, 1 H), 3.67 (dd, 3.0 Hz, 10.8 Hz, 1 H), 4.04-4.16 (m, 3 H), 4.30-4.66 (m, 6 
H), 5.69 (d, 6.0 Hz, 1 H), 7.03 (d, 1.2 Hz, 1 H), 7.11 (dd, 2.0 Hz, 7.8 Hz, 2 H), 7.21-
7.42 (m, 13 H), 7.46 (d, 1.2 Hz, 1 H). 13C NMR (CDCl3) δ 60.3, 69.7, 72.3, 72.6, 
73.7, 76.5, 81.6, 82.6, 88.8, 121.9, 127.8, 127.9, 128.0, 128.2, 128.5, 128.6, 136.6, 




119 To a solution of 12b (34.7 g, 48.0 mmol) in anhydrous ether (500 mL) at rt 
was added EtMgBr (3.0 M, 19 mL, 57 mmol) in a dropwise manner. The mixture was 
stirred at rt for 3 h, then quenched with anhydrous EtOH (50 mL). The solvent was 
removed under reduced pressure, saturated aqueous NH4Cl solution (300 mL) added, 
and the mixture extracted with CH2Cl2 (3 x 200 mL). The organic layers were 
combined, washed with brine (2 x 400 mL), dried over MgSO4, and the solvent 
removed under reduced pressure. Column chromatography of the residue, eluting 
with hexane:EtOAc  (3:1) gave 11 as a colorless syrup (23 g, 80%). 1H NMR (CDCl3) 
δ 3.51 (dd, 2.4 Hz, 10.8 Hz, 1 H), 3.67 (dd, 3.0 Hz, 10.8 Hz, 1 H), 4.04-4.16 (m, 3 H), 
4.30-4.66 (m, 6 H), 5.69 (d, 6.0 Hz, 1 H), 7.03 (d, 1.2 Hz, 1 H), 7.11 (dd, 2.0 Hz, 7.8 
Hz, 2 H), 7.21-7.42 (m, 13 H), 7.46 (d, 1.2 Hz, 1 H). 13C NMR (CDCl3) δ 60.3, 69.7, 
72.3, 72.6, 73.7, 76.5, 81.6, 82.6, 88.8, 121.9, 127.8, 127.9, 128.0, 128.2, 128.5,128.6, 
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136.6, 137.1, 137.2, 137.5. Anal. Calcd for C29H29IN2O4: C, 58.40; H, 4.90; N, 4.70; 




 EtMgBr (3.0 M in ethyl ether, 0.62 mL, 1.84 mmol) was added dropwise to a 
solution of 13a (1.0 g, 1.67 mmol) in anhydrous CH2Cl2 (15 mL) at rt under Ar. The 
resulting solution was stirred at rt for 2 h, followed by dropwise addition of 
trimethyltin chloride (1.0 M in CH2Cl2, 2.0 mL, 2.0 mmol) at rt. The mixture was 
allowed to stir at rt for 18 h, then quenched with water. The organic layer was 
separated and the aqueous layer washed with CH2Cl2 (2 x 20 mL). The organic 
extracts were combined, washed sequentially with saturated KF solution (30 mL) to 
form insoluble organotin fluoride, and then with brine (50 mL). The organic layer 
was dried over MgSO4, and the solvent removed to afford 15 as a colorless syrup 
(714 mg, 91%). 1H NMR (CDCl3) δ 3.48 (dd, 2.4 Hz, 10.8 Hz, 1 H), 3.62 (dd, 3.0 Hz, 
10.8 Hz, 1 H), 4.03 (dd, 2.8 Hz, 4.8 Hz, 1 H), 4.10 (br t, 5.4 Hz, 1 H), 4.29 (dd, 2.8 
Hz, 5.4 Hz, 1 H), 4.36-4.61 (m, 6 H), 5.74 (d, 6.4 Hz, 1 H), 6.98 (d, 6.8 Hz, 2 H), 
7.10-7.32 (m, 15 H), 7.59 (s, 1 H). 13C NMR (CDCl3) δ 69.5, 72.0, 72.3, 73.3, 76.4, 
81.4, 82.1, 88.5, 116.1, 127.3, 127.4,127.5, 127.6, 127.7, 128.1, 129.3, 135.7, 136.5, 
137.0, 137.1. 
 
5-Iodo-4(3H)-pyrimidinone (17).  A mixture of 4(3H)-pyrimidinone 16 (1.14 g, 11.8 
mmol), I2 (3.02 g, 11.8 mmol) and H2O (12 mL) was stirred at 80°C for 18 h. The 
solution was neutralized with glacial acetic acid to give a light yellow solid. The solid 
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was recrystallized in hot ethanol to give a white powder (2.37 g, 91%). 1H NMR 
(CDCl3) δ  8.16 (s, 1 H), 8.42 (s, 1 H). 
13C NMR (CDCl3) δ 150.0, 160.3. 
 
Attempted synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-[4-(1,3-dimethyl-5-
pyrimidinyl-2,4-one)imidazol-1-yl]-1-β-D-ribofuranose (18).  To a solution of 13b 
(500 mg, 0.85 mmol) in Et2O was added n-BuLi (1.3 M in hexane, 0.42 mL, 1.02 
mmol) at -78 °C under Ar and the mixture was stirred for 2 h.  Next, 
hexabutyldistannane (0.52 mL, 1,02 mmol) was added, followed by the addition of 
either one of these catalysts; PdCl2(PPh3)2, PdCl2(dppf), Pd(PPh3)4 or  Pd2(dba)3 (5 
mol%).  After refluxing for 12 h, the mixture was cooled and saturated aqueous KF 
(50 mL) was added.  Upon TLC analysis, it was indicative that all of the reactions did 




  Dimethyl sulfate (11.0 mL, 116 mmol) was 
added dropwise to a stirring slurry of 5-bromouracil 19a (10.0 g, 52.4 mmol), NaOH 
(5.24 g, 131 mmol) in H2O (80 mL) at 0 °C. The mixture was heated under reflux for 
2 h, cooled to rt and extracted with CH2Cl2 (3 x 200 mL).  The organic layers were 
combined, washed with brine (300 mL), and dried over MgSO4. The solvent was 
removed under reduced pressure to give a white solid, which, following 
recrystallization in hot EtOH, gave 20a as a white crystalline solid (9.17 g, 80%), mp: 
224 °C (Aldrich, 225 °C). 1H NMR (CDCl3) δ 3.40 (s, 3 H), 3.41 (s, 3 H), 7.62 (s, 1 





  Dimethyl sulfate (13.0 mL, 137 mmol) was 
added dropwise to a stirring slurry of 5-iodouracil 19b (14.9 g, 62.6 mmol), NaOH 
(7.4 g, 156 mmol) in H2O (100 mL) at 0 °C. The mixture was heated under reflux for 
2 h, cooled to rt and extracted with CH2Cl2 (3 x 200 mL).  The organic layers were 
combined, washed with brine (300 mL), and dried over MgSO4. The solvent was 
removed under reduced pressure to give a white solid, which, following 
recrystallization in hot EtOH, gave 20b as a white crystalline solid (13.5 g, 63%), mp: 
224 °C (Aldrich, 225 °C). 1H NMR (CDCl3) δ 3.40 (s, 3 H), 3.41 (s, 3 H), 7.62 (s, 1 
H) 13C NMR (CDCl3) 29.5, 37.3, 67.1, 147.2, 151.2, 160.2.  
 
Attempted synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-[4-(1,3-dimethyl-5-
pyrimidinyl-2,4-dione)imidazol-1-yl]-1-β-D-ribofuranose (21).  EtMgBr (3.0 M in 
Et2O, 140 L, 0.420 mmol) was added dropwise to a stirred solution of 13b (220 mg, 
0.368 mmol) in anhydrous Et2O (40 mL) at room temperature under Ar.  The mixture 
was allowed to stir for 1 h.  Next, ZnCl2 (1.0 M in Et2O, 400 L, 0.40 mmol) was 
added dropwise to the mixture and allowed to stir for 1 h under Ar at rt.  In a separate 
flask charged with Ar, a mixture of 5-iodo-1,3-dimethyluracil (20b) (107 mg, 0.405 
mmol) and Pd(PPh3)4, PdCl2(PPh3)2, PdCl2(dppf) or Pd2(dba)3 (5 mol %)in CH2Cl2 
was stirred at rt for 15 min.  To this mixture was added the Grignard reagent 
(prepared in the first flask) was slowly added and the resulting mixture as stirred for 6 
h at rt.  Upon TLC analysis, it was indicative that all of the reactions did not show 
formation of 21. 
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Attempted synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-[4-(1,3-dimethyl-5-
pyrimidinyl-2,4-dione)imidazol-1-yl]-1-β-D-ribofuranose (21).  EtMgBr (3.0 M in 
THF, 150 L, 0.450 mmol) was added dropwise to a stirred solution of 13b (235 mg, 
0.394 mmol) in anhydrous Et2O (35 mL) at room temperature under Ar.  The mixture 
was allowed to stir for 1 h.  Next, ZnCl2 (1.0 M in Et2O, 450 L, 0.45 mmol) was 
added dropwise to the mixture and allowed to stir for 1 h under Ar at rt.  In a separate 
flask charged with Ar, a mixture of 5-bromo-1,3-dimethyluracil (20a) (95 mg, 0.433 
mmol) and Pd(PPh3)4, PdCl2(PPh3)2, PdCl2(dppf) or Pd2(dba)3 (5 mol %) in CH2Cl2 
was stirred at rt for 15 min.  To this mixture was added the Grignard reagent 
(prepared in the first flask) was slowly added and the resulting mixture as stirred for 6 
h at rt.  Upon TLC analysis, it was indicative that all of the reactions did not show 
formation of 21. 
 
Attempted synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-[4-(1,3-dimethyl-5-
pyrimidinyl-2,4-dione)imidazol-1-yl]-1-β-D-ribofuranose (21).  EtMgBr (3.0 M in 
THF, 285 L, 0.854 mmol) was added dropwise to a stirred solution of 13b (463 mg, 
0.776 mmol) in CH2Cl2 (50 mL) at room temperature under Ar.  The mixture was 
allowed to stir for 30 min.  Next, ZnCl2 (1.0 M in Et2O, 0.78 mL, 0.78 mmol) was 
added dropwise to the mixture and allowed to stir for 1 h under Ar at rt.  To the 
mixture was added a solution of 5-iodo-1,3-dimethyluracil (20b) (206 mg, 0.776 
mmol) and PdCl2(dppf) (50 mg, 0.061 mmol) in anhydrous DMF (5 mL).  The 
solution was stirred under Ar at rt for 18 h.  The solvent was removed under reduced 
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pressure.  Upon TLC analysis (3% EtOH in CH2Cl2), it was indicative that all of the 




 Bromine (100 mL, 1.95 mol) was added dropwise to a 
suspension of uracil (100 g, 0.89 mol) in H2O (400 mL) while stirring. The reaction 
was allowed to stir overnight.  Next, the solvent and excess reagents were evaporated 
at 100 °C. The residue was decolorized with activated carbon and recrystallized in hot 
H2O to produce 23 as a colorless crystalline solid (150 g, 88% yield). mp > 300°C 
(from Aldrich > 300 °C).  1H NMR (DMSO-d6) δ 2.71 (s, 3 H), 2.74 (s, 3 H), 8.26 (s, 
1 H) 13C NMR (DMSO-d6) δ 28.4, 35.0, 91.6, 141.7, 154.0, 162.1. 
 
5-Bromo-2,4-dichloropyrimidine (24).
147 A mixture of 23 (50.0 g, 0.262 mol), 
POCl3 (250 mL, 2.68 mol), and diethylaniline (60 mL, 0.377 mol) was heated under 
reflux for 100 min. Then 24 was subsequently isolated via distillation under reduced 
pressure (110-120 ºC/10 mmHg) (Ref. 112-113 ºC/12 mmHg) to afford a colorless 
liquid (54.3 g, 91%). 1H NMR (DMSO-d6) δ 8.94 (s, 1 H) 
13C NMR (DMSO-d6) δ 




  A mixture of 
24 (5.5 g, 24.1 mmol), thiourea (4.1 g, 53.9 mmol) in anhydrous EtOH (50 mL) was 
heated under reflux for 30 minutes.148 After cooling at 0°C, the precipitate was 
filtered, washed with cold EtOH and then diethyl ether to yield 24 as yellow 




 An aqueous solution of 25 (5.6 g, 
10.8 mmol) in NaOH (10%, 45 mL) was heated at 110°C for 1 h. The hot solution 
was slowly acidified with acetic acid to afford a yellow precipitate. The precipitate 
was filtered, washed with H2O and EtOH, and then re-precipitated from a hot dilute 
NaOH solution by addition of acetic acid to give 25 as a yellow powder (2.8 g, 84% 




  A mixture of 26 (2.8 g, 12.5 
mmol) and NaOH (4.5 g) in H2O (40 mL) was stirred to form a yellow solution. 
Dimethylsulfate (3.6 mL, 38 mmol) was added dropwise, and the mixture stirred for 
30 min at rt.148 The mixture was extracted with diethyl ether (3 x 50 mL). The 
extracts were combined, washed with brine (50 mL), dried over MgSO4 and the 
solvent removed under reduced pressure to give a yellow-orange solid. The solid was 
recrystallized in EtOH, followed by a second recrystallization in hexanes to afford 26 
as a yellow crystalline solid (2.4 g, 76% yield), mp: 63-65°C. 1H NMR (CDCl3) δ 




imidazol-1-yl]-1-β-D-ribofuranose (29).145 EtMgBr (3.0 M in Et2O, 140 µL, 0.420 
mmol) was added dropwise to a stirred solution of 13b (220 mg, 0.368 mmol) in 
anhydrous CH2Cl2 (10 mL) at rt under Ar and was stirred for 1 h. ZnCl2 (1.0 M in 
Et2O, 400 µL, 0.40 mmol) was added dropwise. The mixture was then stirred at rt for 
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an additional 1 h under Ar. The suspension formed was added to a solution of 27 
(70.8 mg, 0.405 mmol) and Pd(PPh3)4 in anhydrous CH2Cl2 (15 mL), and the mixture 
stirred overnight. The solvent was removed under reduced pressure, saturated 
aqueous NH4Cl solution (10 mL) was added, and the mixture was extracted with 
CH2Cl2 (3 x 25 mL). The organic extracts were combined, washed with brine (25 
mL), dried over MgSO4 and the solvent removed under reduced pressure to produce a 
yellow syrup. Column chromatography eluting with 2% EtOH in CH2Cl2 yielded 29 
as a colorless syrup (132 mg, 67% yield). 1H NMR (CDCl3) δ 
1H NMR (CDCl3) δ 
2.54 (s, 3 H), 3.52 (dd, 2.4 Hz, 10.8 Hz, 1 H), 3.66 (dd, 2.4 Hz, 10.8 Hz, 1 H), 4.06 
(br s, 3 H), 4.09-4.15 (m, 1 H), 4.22 (br s, 1 H), 4.32-4.64 (m, 6 H), 5.75 (d, 5.6 Hz, 1 
H), 7.01-7.53 (m, 15 H), 7.79 (br s,1 H), 7.92 (br s, 1 H), 8.44 (s, 1 H). 13C NMR 
(CDCl3) δ 30.1, 69.9, 72.7, 73.2, 73.8, 76.8, 82.1, 82.4, 82.9, 88.6, 115.6, 117.2, 
120.2, 127.8, 128.0, 128.1, 128.2, 128.3, 128.4,128.5, 128.6, 128.7, 128.8, 132.1, 
136.9, 137.5, 155.5, 158.4, 169.3.  
 
Attempted synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-[4-
(dihydroxyboryl)-imidazol-3-yl]-1-β-D-ribofuranose (30).  N-Butyllithium (1.3 M 
in hexane, 0.14 mL, 0.34 mmol) was dropwise added over a 1 h period to a solution 
of 13b (170 mg, 0.29 mmol) and B(OiPr)3 (0.09 mL, 0.29 mmol) in anhydrous THF 
(50 mL total) at –78 ºC under Ar.  The mixture was stirred for an additional 8 h at rt, 
followed by addition of dilute HCl (1 M). The residue was then treated with H2O (50 
mL) and extracted with CH2Cl2 (3 x 30 mL). The organic extracts were combined, 
washed with brine (50 mL), dried over MgSO4 and the solvent removed under 
 122 
reduced pressure to give the dehalogenatged nucleoside 15 as a white powder.  1H 
NMR (CDCl3) δ 3.48 (dd, 2.4 Hz, 10.8 Hz, 1 H), 3.62 (dd, 3.0 Hz, 10.8 Hz, 1 H), 
4.03 (dd, 2.8 Hz, 4.8 Hz, 1 H), 4.10 (br t, 5.4 Hz, 1 H), 4.29 (dd, 2.8 Hz, 5.4 Hz, 1 H), 
4.36-4.61 (m, 6 H), 5.74 (d, 6.4 Hz, 1 H), 6.98 (d, 6.8 Hz, 2 H), 7.10-7.32 (m, 15 H), 
7.59 (s, 1 H). 13C NMR (CDCl3) δ 69.5, 72.0, 72.3, 73.3, 76.4, 81.4, 82.1, 88.5, 116.1, 
127.3, 127.4,127.5, 127.6, 127.7, 128.1, 129.3, 135.7, 136.5, 137.0, 137.1. 
 
Attempted synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-[4-
(pinacolatoboryl)-imidazol-3-yl]-1-β-D-ribofuranose (31).  A mixture of 13b (775 
mg, 1.3 mmol), bis(pinacolato)diboron (363 mg, 1.43 mmol), anhydrous potassium 
acetate (383 mg, 3.9 mmol) and PdCl2(dppf) (32 mg, 0.039 mmol) in DMF (10 mL) 
was heated under Ar at 80 ºC for 2 h. An additional amount of PdCl2(dppf) (32 mg, 
0.039 mmol) was added to the reaction mixture and was stirred overnight. Upon TLC 
observation, the reaction failed to afford 31 and only starting material 30 was 
recovered.  
 
5-Tri-n-butylstannyl-1,3-dimethyluracil (32). A mixture of 5-iodo-1,3-
dimethyluracil (20b) (2.66 g, 10.0 mmol), bis(tributyltin) (10.1 mL, 20.0 mmol) and 
PdCl2(PPh3)4 (280 mg, 0.40 mmol) in anhydrous toluene (300 mL) was heated under 
Ar at 90 °C for 4 h. The mixture was filtered through a plug of alumina. The solvent 
was removed under reduced pressure and the product was purified by column 
chromatography (silica was pretreated with 5% triethylamine in hexane; eluted with 
2% triethylamine in hexane) to afford a colorless oil (2.87 g, 66%). 1H NMR (CDCl3) 
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δ 0.88 (t, 7.2 Hz, 9 H), 1.03 (t, 8.4 Hz, 6 H), 1.31 (q, 7.6 Hz, 6 H), 1.50 (q, 8.4 Hz, 6 
H), 3.32 (s, 3 H), 3.36 (s, 3 H), 6.87 (s, 1 H) 13C NMR (CDCl3) δ 9.9, 13.8, 27.4, 
27.7, 29.1, 36.8, 111.0, 146.7, 152.4, 166.5. 
 
Attempted synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-[4-(1,3-dimethyl-5-
pyrimidinyl-2,4-dione)imidazol-1-yl]-1-β-D-ribofuranose (21).  In a 50 mL, 3-neck 
round bottom flask was charged with Pd(PPh3)4 (15 mg, 0.013 mol), CuI (5 mg, 
0.026 mol) and 13b (936 mg, 1.57 mmol) in anhydrous DMF (10 mL) under Ar.  To 
this mixture was added dropwise a solution of 32 (525 mg, 1.22 mmol) in anhydrous 
DMF (5 mL).  The mixture was heated at 80 °C under Ar for 12 h.  At suitable time 
intervals, a part of the reaction mixture was sampled and subjected to TLC analysis.  
Upon TLC analysis (2% EtOH in CH2Cl2), it indicated that the reactions did not show 
formation of 21. 
 
Attempted synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-[4-(1,3-dimethyl-5-
pyrimidinyl-2,4-dione)imidazol-1-yl]-1-β-D-ribofuranose (21).  In a 50 mL, 3-neck 
round bottom flask was charged with PdCl2(PPh3)2 (12.5 mg, 0.018 mol), CuI (6 
mg, 0..036 mol) and 13b (750 mg, 1.26 mmol) in anhydrous DMF (10 mL) under 
Ar.  To this mixture was added dropwise a solution of 32 (430 mg, 1.00 mmol) in 
anhydrous DMF (5 mL).  The mixture was heated at 80 °C under Ar for 12 h.  At 
suitable time intervals, a part of the reaction mixture was sampled and subjected to 
TLC analysis.  Upon TLC analysis (2% EtOH in CH2Cl2), it indicated that the 
reactions did not show formation of 21. 
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Attempted synthesis of 5-iodozinc-1,3-dimethyluracil (34) to afford 2,3-
dibenzyloxy-5-benzyloxymethyl-1-[4-(1,3-dimethyl-5-pyrimidinyl-2,4-
dione)imidazol-1-yl]-1-β-D-ribofuranose (21).  In a 50 mL, 3-neck round bottom 
flask was charged with 5-iodo-1,3-dimethyluracil (20b) (452 mg, 2.0 mmol), Zn 
powder (190 mg, 3.0 mmol), N,N-dimethylacetamide (3 mL) and 1,2-dibromoethane 
(57 mg, 0.3 mmol).  The mixture was heated for 10 min at 80 °C and then cooled to 
rt.  This was followed by the addition of Me3SiCl (45 L, 36 mmol) and the mixture 
was heated to rt.  To this mixture was added a solution of 13b (1.19 g, 2.0 mmol) and 
Pd(PPh3)4 (50 mg, 0.043 mmol) in anhydrous DMF (5 mL).  The solution was stirred 
under Ar at rt for 18 h.  The solvent was removed under reduced pressure.  Upon TLC 
analysis (3% EtOH in CH2Cl2), it was indicative that all of the reactions did not show 
formation of 21. 
 
5-Bromo-2,4-dibenzyloxypyrimidine (35).
157  A stirred solution of benzyl alcohol 
(13.4 mL, 129 mmol) in anhydrous toluene (140 mL) was treated with NaH (60% in 
mineral oil, 4.84 g, 121 mmol) under Ar. The mixture was warmed to 50 °C to 
facilitate the formation of the sodium salt, and stirred until all signs of gas evolution 
had subsided. The suspension was cooled and 5-bromo-2,4-dichloropyrimidine (24) 
(9.1 g, 40 mmol) was added dropwise, while maintaining the temperature below 25 
°C. After stirring for 18 h at rt, the reaction was filtered to remove precipitated NaCl, 
and thoroughly washed with toluene. The filtrate was then evaporated under reduced 
pressure to give an oil, which solidified upon cooling. The crude solid was then 
recrystallized in EtOH to afford 35 as a white crystalline solid (16 g, 91%). mp: 88-
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90°C. (Lit. 89-91 ºC) 1H NMR (CDCl3) δ 5.40 (s, 2 H), 5.48 (s, 2 H), 7.32-8.48 (m, 
10 H), 8.35 (s, 1 H). 13C NMR (CDCl3) δ 69.1, 69.7, 98.4, 127.7, 128.0, 128.1, 128.2, 
128.5, 128.6, 135.5, 136.1, 159.4, 159.5, 163.5, 166.2. 
 
5-(Dihydroxyboryl)-2,4-bis(benzyloxy)pyrimidine (36).  a) sequential method.
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A solution of 5-bromo-2,4-dibenzyloxypyrimidine (35) (1.0 g, 2.7 mmol) in THF (10 
mL) was added dropwise to a solution of n-BuLi (1.3 M in hexane, 2.5 mL, 3.2 
mmol) in THF (30 mL) at -78°C under Ar. The resulting solution was stirred at -78 
°C for 10 min and a solution of B(OiPr)3 (1.0 mL, 5.3 mmol) in THF (4 mL) was 
added dropwise. The reaction mixture was stirred at -78 °C for 1 h, warmed to room 
temperature for 2 h. Then the reaction mixture was quenched with hydrochloric acid 
(3 M, 9 mL). After 2 h at room temperature, the mixture was diluted with ethyl 
acetate (30 mL) and phases were separated. The aqueous layer was extracted with 
ethyl acetate (2 x 30 mL), and the combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified through column 
chromotography eluting with 3% ethanol in methylene chloride to give comound as a 
colorless syrup (199 mg, 22%). 1H NMR (CDCl3) δ 5.46 (s, 4 H), 7.25-7.48 (m, 10 
H), 8.72 (s, 1H); 13C NMR (CDCl3) δ 118.5, 160.1, 161.4, 165.9.  b) one-pot 
method.
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 N-Butyllithium (1.3 M in hexane, 2.5 mL, 3.2 mmol) was dropwise added 
over a 1 h period to a solution of 35 (1.0 g, 2.7 mmol) and B(OiPr)3 (1.0 mL, 5.3 
mmol) in a mixture of anhydrous THF and toluene (1:4 volume ratio, 50 mL total) at 
–78 ºC under Ar. The mixture was stirred for an additional 18 h at rt, followed by 
addition of dilute HCl (1 M). The residue was then treated with H2O (50 mL) and 
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extracted with CH2Cl2 (3 x 30 mL). The organic extracts were combined, washed 
with brine (50 mL), dried over MgSO4 and the solvent removed under reduced 
pressure to give 36 as a white powder (860 mg, 95%).  1H NMR (CDCl3) δ 5.46 (s, 4 




imidazol-1-yl]-β-D-ribofuranose (37).158 A mixture of 13b (1.7 g, 2.9 mmol) and 
Pd(PPh3)4 (185 mg, 0.16 mmol) in 40 mL of 1,2-dimethoxyethane (DME) was stirred 
at rt under Ar for 10 min. To this mixture, 5-(dihydroxyboryl)-2,4-bis(benzyloxy)-
pyrimidine (36) (3.2 mmol in 20 mL DME) was added. Saturated aqueous NaHCO3 
(40 mL) was added, and the mixture refluxed under Ar for 4 h. The solution was 
cooled to rt, the DME layer separated and set aside. The aqueous layer was then 
extracted with EtOAc (3 x 50 mL) and the organic extracts combined with the DME 
layer, washed with brine (100 mL), and dried over MgSO4. The solvent was removed 
to give a pale brown syrup. Column chromatography eluting with 2% EtOH in 
CH2Cl2 gave 37 as a colorless syrup (1.47 g, 70%). 
1H NMR (CDCl3) δ 3.45 (dd, 3.0 
Hz, 10.6 Hz, 1 H), 3.56 (dd, 3.3 Hz, 10.6 Hz, 1 H), 4.01-4.48 (m, 1 H), 4.11 (br t, 5.5 
Hz, 1 H), 4.31-4.62 (m, 7 H), 5.42-5.52 (m, 4 H), 5.78 (d, 6.0 Hz, 1 H), 7.15-7.54 (m, 
26 H), 7.73 (s, 1 H), 9.15 (s, 1 H). 13C NMR (CDCl3) δ 68.3, 68.9, 69.4, 72.1, 72.5, 
73.1, 76.5, 81.5, 82.1, 88.7, 109.5, 115.6, 127.3, 127.6, 127.8, 127.9, 128.3, 134.0, 
135.6, 136.1, 136.5, 136.7, 137.2, 137.3, 155.9, 162.7, 166.0. Anal. Calcd for 
C47H44N4O6•1H2O: C, 72.48; H, 5.95; N, 7.19. Found: C, 72.82; H, 5.75; N, 7.03. 
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1-[4-(Uracil-5-yl)imidazol-1-yl]-1-β-D-ribofuranose 2,3,5-Triol (6).115 A mixture 
of 37 (200 mg, 0.26 mmol), palladium (10% Pd/C, 200 mg) and ammonium formate 
(300 mg) in EtOH (50 mL) was heated under reflux for 2 h. The solvent was then 
removed under reduced pressure and the residue purified by column chromatography 
eluting with EtOAc:acetone:EtOH:H2O (7:1:1:0.5) to give 6 as a white crystalline 
solid (72 mg, 88%), mp: 239-242°C. 1H NMR (DMSO-d6) δ 3.49 (dd, 4.5 Hz, 12.3 
Hz, 1 H), 3.55 (dd, 5.0 Hz, 12.3 Hz, 1 H), 3.86 (br d, 3.3 Hz, 1 H), 4.0 (dd, 4.0 Hz, 
6.0 Hz, 1 H), 4.11 (br t, 5.1 Hz, 1 H), 5.00 (br t, 4.8 Hz, 1 H), 5.14 (br d, 3.9 Hz, 1 H), 
5.36 (br d, 5.7 Hz, 1 H), 5.52 (d, 6.0 Hz, 1 H), 7.67 (s, 1 H), 7.81 (s, 1 H), 7.86 (s, 1 
H). 11.0 (s, 1 H), 112.2 (s, 1 H). 13C NMR (DMSO-d6) δ 61.3, 70.3, 75.1, 85.2, 89.3, 
107.3, 114.5, 133.5, 135.7, 136.3, 150.5, 162.2. Anal. Calcd for C12H14N4O6•0.6H2O: 
C, 44.88; H, 4.80; N, 17.38. Found: C, 45.14; H, 4.60; N, 17.03. 
 
Attempted synthesis of 1-[4-(4-aminopyrimidin-5-yl-2-one)imidazol-1-yl]-1-β-D-
ribofuranose 2,3,5-Triol (4).
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  1-[4-(Uracil-5-yl)imidazol-1-yl]-1--D-ribofuranose 
2,3,5-Triol (6) (27.4 mg, 88.3 mol), formamidine (7.04 L, 177 mol), 
hexamethyldisilazane (280 L, 1.33 mmol) and ammonium sulfate  (13 mg, 98.5 
mol) were combined in a Parr bomb and stirred at 120 °C for 72 h.  After cooling to 
rt, the contents of the bomb were dissolved in methanol and refluxed for 6 h.  Upon 








ribofuranose 2,3,5-Triol (6) (75 mg, 241 mol) and DMF-dimethylacetal (10 mL) 
was heated to 80 °C for 6 h.  The reaction mixture as cooled to rt, and the solvent was 
removed under reduced pressure to afford 38 as an off-white powder (39 mg, 48%).  
The product was used without purification.  MS (ESI): Calc’d for C14H18N4O6: 338. 
Found: (M+1) 339. 
 
Attempted synthesis of 1-[4-(2-aminopyrimidin-5-yl-4-one)imidazol-1-yl]-1-β-D-
ribofuranose 2,3,5-Triol (3).
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  Guanidine HCl (100 mg, 1.05 mmol) was stirred in 
a 0.7 M sodium ethoxide (20 mL) for 10 min and the NaCl salt was removed by 
filtration.  To the filtrate was added (35 mg, 0.103 mmol) and the reaction was 
refluxed for 18 h.   The solvent was removed under reduced pressure.  Upon TLC 
analysis in a mobile phase of EtOAc:acetone:EtOH:H2O (4:1:1:0.5), it was indicative 
that all of the reactions did not show formation of 3.   
 
2,3-Dibenzyloxy-5-benzyloxymethyl-1-[4-(2,4-diaminopyrimidine)-imidazol-1-
yl]-1-β-D-ribofuranose (39).162 In a Parr bomb, anhydrous ammonia gas was bubbled 
in an anhydrous methanolic solution of 37 (1.0 g, 1.3 mmol in 50 mL of methanol) at 
–78 ºC for 5 min. The bomb was sealed and heated at 170 ºC for 96 h. After cooling 
to 0 ºC, the solvent was removed under reduced pressure. The residue was purified by 
column chromatography eluting with 8% EtOH in CH2Cl2 to give 39 (306 mg, 40%) 
a colorless syrup. 1H NMR (CDCl3) δ 3.54 (dd, 2.4 Hz, 10.4 Hz, 1 H), 3.70 (dd, 2.8 
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Hz, 10.4 Hz, 1 H), 4.09 (dd, 2.5 Hz, 4.5 Hz, 1 H), 4.16 (br t, 4.8 Hz, 1 H), 4.33-4.36 
(m, 1 H), 4.39 (d, 12.0, 1 H), 4.47-4.68 (m, 6 H), 5.06 (br s, 2 H), 5.66 (br s, 2 H), 
5.74 (d, 6.4 Hz, 1 H), 7.01 (s, 1 H), 7.10-7.35 (m, 15 H), 7.60 (s, 1 H), 7.78 (s, 1 H). 
13C NMR (CDCl3) δ 70.2, 72.7, 73.0, 74.0, 76.9, 81.7, 82.9, 89.2, 102.6, 110.4, 127.3, 
127.8, 128.0, 128.1, 128.2, 128.3, 128.4, 128.5, 128.7, 128.8, 129.0, 135.3, 136.9, 




115 In a similar fashion as was used to obtain 6, the desired triol 5 was obtained in 
90% yield (159 mg) as a white powder following deprotection of 39 with Pd/C and 
ammonium formate. Mp: 268-272 °C. 1H NMR (DMSO-d6) δ 3.72 (dd, 3.6 Hz, 12.0 
Hz, 1 H), 3.80 (dd, 3.2 Hz, 12.0 Hz, 1 H), 4.05 (q, 3.2 Hz, 1 H), 4.20, (dd, 3.6 Hz, 4.2 
Hz, 1 H), 4.27 (br t, 4.2 Hz, 1 H), 5.64 (d, 5.6 Hz, 1 H), 7.56 (s, 1 H), 7.91 (s, 1 H), 
7.96 (s, 1 H).  13C NMR (DMSO-d6) δ 61.4, 70.4, 75.1, 85.4, 89.4, 100.6, 111.0, 
135.5, 137.5, 150.4, 160.3, 160.5. Anal. Calcd for C12H16N6O4•1H2O: C, 45.42; H, 





  To a solution of 39 (850 mg, 1.46 mmol) in a 1:1 mixture of THF and H2O (30 
mL) was added sodium nitrite (486 mg, 7.03 mmol), followed by glacial acetic acid 
(0.62 mL, 10.69 mmol).  The mixture was heated to 60 °C and stirred for 2 hours, at 
which point the TLC showed no traces of starting material. The solution was cooled 
to rt, neutralized with concentrated NH4OH (1 mL) and evaporated under reduced 
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pressure. The crude product was used directly in the next step. In a similar fashion as 
was used for the deprotection of 37 to get 6, the benzyl groups were deblocked with 
Pd/C and ammonium formate in refluxing ethanol, and subsequently purified by 
column chromatography eluting with EtOAc:acetone:EtOH:H2O (4:1:1:0.5) to give 4 
as a white powder (42 mg, 41% for 2 steps).  1H NMR (D2O) δ 3.61 (dd, 3.6 Hz, 12.0 
Hz, 1 H), 3.71 (dd, 3.2 Hz, 12.0 Hz, 1 H), 4.06 (q, 3.2 Hz, 1 H), 4.19, (dd, 3.6 Hz, 4.2 
Hz, 1 H), 4.33 (dd, 1 H), 5.68 (d, 3.9 Hz, 1 H), 7.39 (s, 1 H), 7.56 (s, 1 H), 7.89 (s, 1 
H), 8.23 (s, 2H). 13C NMR (D2O) δ 61.7, 70.3, 75.0, 85.1, 89.5, 101.1, 115.1, 134.2, 
137.7, 158.5, 165.1, 171.1. 
 
1-[4-(2-Aminopyrimidin-5-yl-4-one)imidazol-1-yl]-1-β-D-ribofuranose 2,3,5-Triol 
(3).  A solution of 5 (14 mg, 0.05 mmol) and saturated aqueous NaHSO3 (5.0 mL) 
was heated at 60 ºC for 10 hours. The solution was evaporated under reduced pressure 
to afford the crude product, which was purified by preparative TLC eluting with 
EtOAc:acetone:EtOH:H2O (4:1:1:1) to obtain 3 as a white powder (12.4 mg, 88%). 
1H NMR (D2O): δ 3.70 (dd, 3.3 Hz, 10.2 Hz, 1H), 3.87 (dd, 2.4 Hz, 10.2 Hz, 1H), 
4.07-4.16 (m, 2H), 4.29 (dd, 2.4 Hz, 4.5 Hz, 1H), 6.11 (s, 1 H), 6.38 (d, 5.7 Hz, 1 H), 
7.84 (d, 1.2 Hz, 1H), 9.14 (dd, 0.6 Hz, 1.5 Hz, 1 H). 13C NMR (D2O) δ 60.1, 69.0, 
75.9, 85.4, 91.6, 105.0, 122.5, 130.0, 135.8, 145.3, 154.0, 163.4.  Anal. Calcd for 





yl]-1-β-D-ribofuranose (42).152  A mixture of 13b (656 mg, 1.10 mmol) and 
PdCl2(dppf) (24 mg, 0.03 mmol) in DMF (20 mL) was stirred at room temperature 
under Ar for 10 min. This was added to a solution of 5-(dihydroxyboryl)pyrimidine 
(41) (124 mg, 1.0 mmol in 20 mL DMF), followed by addition of a saturated aqueous 
2M Na2CO3 solution (2.5 mL). The mixture was heated at 80 ºC under Ar for 18 h, 
followed by cooling to rt. The volume was reduced and the residue extracted with 
EtOAc (3 x 20 mL). The organic extracts were combined, and washed sequentially 
with H2O (30 mL), then brine (50 mL), and dried over MgSO4. The solvent was 
removed under reduced vacuum to give a tan syrup. Column chromatography eluting 
with 2% EtOH in CH2Cl2 gave 42 as a colorless syrup (362 mg, 66%). 
1H NMR 
(CDCl3) δ 3.45 (dd, 3.0 Hz, 10.6 Hz, 1 H), 3.56 (dd, 3.3 Hz, 10.6 Hz, 1 H), 4.01-4.48 
(m, 1 H), 4.11 (br t, 5.5 Hz, 1 H), 4.31-4.62 (m, 7 H), 5.42-5.52 (m, 4 H), 5.78 (d, 6.0 
Hz, 1 H), 7.15-7.54 (m, 26 H), 7.73 (s, 1 H), 9.15 (s, 1 H). 13C NMR (CDCl3) δ 68.3, 
68.9, 69.4, 72.1, 72.5, 73.1, 76.5, 81.5, 82.1, 88.7, 109.5, 115.6, 127.3, 127.6, 127.8, 
127.9, 128.3, 134.0, 135.6, 136.1, 136.5, 136.7, 137.2, 137.3, 155.9, 162.7, 166.0. 
Anal. Calcd for C47H44N4O6•1H2O: C, 72.48; H, 5.95; N, 7.19. Found: C, 72.82; H, 
5.75; N, 7.03. 
 
Attempted synthesis of 2,3-dibenzyloxy-5-benzyloxymethyl-1-[4-(4-
aminopyrimidine)-imidazol-1-yl]-1-β-D-ribofuranose (43).175  To a stirred solution 
of liquid ammonia (20 mL) containing potassium amide (2.5 eq), the substrate (1-2 
mole) was added.  After 10 minutes, KMnO4 (3.5 eq) was added portion-wise and 
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stirring was continued for 20 minutes.  The reaction mixture was then quenched with 
ammonium sulfate (5 equivalents) and after 10 minutes methanol (20 mL) was added 
through the condenser.  The ammonia was evaporated under reduced pressure and 
according to the TLC and MS showed decomposition of the starting material. 
 
4(5)-Cyanomethylimidazole (45).165  Commercial bleach Clorox (active ingredient: 
sodium hypochlorite, 30 mL, 95 mmol) was added dropwise to a stirred suspension of 
histidine monohydrochloride monohydrate (10.4 g, 50 mmol) in H2O (30 mL) at 0 
°C. The resulting yellow solution was kept at 10-20 °C for 3 h and the stirring 
allowed to continue for 18 h at rt. Solid sodium carbonate was added until the pH 
reached 8.0. The solution was evaporated to dryness, and the residue triturated with 
refluxing EtOAc (4 x 150 mL). The organic extracts were combined, washed with 
brine (300 mL), dried over MgSO4 and the solvent removed under vacuum. 
Recrystallization of the residue in ethanol gave 45 as a yellow crystalline solid (4.5 g, 
70%), mp: 135-137 ºC. 1H NMR (DMSO-d6) δ 3.84 (s, 2 H), 7.05 (s,1 H), 7.64 (s, 1 
H), 12.09 (s, 1 H). 13C NMR (DMSO-d6) δ 16.5, 114.4, 118.8, 129.5, 135.6. 
 
2,3-Diacetoxy-5-acetoxymethyl-1-(4-cyanomethylimidazol-3-yl)-β-D-
ribofuranose (46a).123 A mixture of 4(5)-cyanomethylimidazole (45) (2.18 g, 2.03 
mmol), 1,2,3,5-tetra-O-acetate-β-D-ribofuranose (7.10 g, 2.25 mmol) and BSA (20 
mL, 8.1 mmol) in acetonitrile (100 mL) was stirred at rt for 3 h under Ar. The 
solution was cooled to 0 °C, and TMSOTf (4.3 mL, 2.25 mmol) was added dropwise. 
The mixture was stirred at 60 °C for 18 h under Ar, then cooled to 0 °C and quenched 
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with aqueous NaHCO3 (50 mL). The organic solvent was removed, and the residue 
extracted with CH2Cl2 (3 x 50 mL). The organic extracts were combined, washed 
with brine (100 mL), dried over MgSO4 and the solvent removed under vacuum to 
give a brown syrup. Column chromatography eluting with 2% ethanol in CH2Cl2 gave 
45 as a pale yellow syrup (1.6 g, 35%). 1H NMR (CDCl3) δ 2.05 (s, 3 H), 2.08 (s, 3 
H), 2.11 (s, 3 H), 3.81 (d, 4.0 Hz, 1 H), 4.36-4.42 (m, 3 H), 5.79 (d, 6.0 Hz, 1 H), 7.16 
(s, 1 H), 7.77 (s, 1 H). MS (ESI): Calc’d for C16H19N3O7: 365. Found: (M+1) 366. 
 
1-[4-(4-Aminopyrimidin-5-yl)imidazol-1-yl]-1)-β-D-ribofuranose 2,3,5-triol (1).168  
A mixture of 11 (1.60 g, 4.38 mmol), sodium methoxide (2 equivalents, made fresh 
from dissolving 202 mg of sodium metal in 10 mL of anhydrous methanol) and 
commercially available 1,3,5-triazine (356 mg, 4.38 mmol) was heated under Ar at 40 
°C for 18 h. Silica gel was added to the reaction mixture and the solvent was removed 
under reduced pressure. The silica gel containing the product was loaded on silica gel 
column and eluted with EtOAc:acetone:EtOH:H2O (8:1:1:0.5) to give 1 as a 
hygroscopic foam (272 mg, 15 %). 1H NMR (CD3OD) δ 3.65 (dd, 3.6 Hz, 12.8 Hz, 
1H), 3.72 (dd, 3.2 Hz, 12.8 Hz, 1 H), 3.97 (q, 3.5 Hz, 1 H), 4.15 (dd, 4.0 Hz, 5.2 Hz, 1 
H), 4.36 (t, 5.2 Hz, 1 H), 5.36 (d, 6.0 Hz, 1 H), 7.08 (s, 1 H), 8.05 (s, 1 H), 8.22 (s, 1 
H), 8.39 (s, 1 H). 13C NMR (CD3OD) δ 61.5, 70.7, 75.9, 85.7, 89.3, 126.6, 128.7, 




1-[4-(Pyrimidin-5-yl-2-one)imidazol-1-yl]-1)-β-D-ribofuranose 2,3,5-Triol (2).162  
To a solution of 1 (400 mg, 1.36 mmol) in a 1:1 mixture of THF and H2O (60 mL) 
was added sodium nitrite (430 mg, 6.23 mmol), followed by glacial acetic acid (0.54 
mL, 9.69 mmol).  The mixture was heated to 80 °C and stirred for 5 hours, at which 
point the TLC showed no traces of starting material. The solution was cooled to room 
temperature, neutralized with concentrated NH4OH (1 mL) and evaporated under 
reduced pressure. The crude product was purified by column chromatography eluting 
with EtOAc:acetone:EtOH:H2O (8:1:1:0.5) to give 2 as a white powder (272 mg, 
68%). 1H NMR (CD3OD) δ 3.68 (dd, 3.5 Hz, 12.8 Hz, 1 H), 3.75 (dd, 3.2 Hz, 12.8 
Hz, 1 H), 4.01 (q, 3.1 Hz, 1 H), 4.11, (dd, 3.8 Hz, 5.1 Hz, 1 H), 4.29 (dd, 2 H), 5.43 
(d, 3.6, 1 H), 7.69 (s, 1 H), 7.92 (s, 1 H), 8.01 (s, 1 H), 8.14 (s, 1 H), 8.48 (bs, 1 H).  
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